Quinazoline compound and use thereof

Through the design and synthesis of quinazoline compounds, the problem of inefficient KRAS G12D mutant protein inhibitors has been solved, and effective inhibition of KRAS G12D mutant protein has been achieved, and the potential treatment of KRAS-related cancers has been achieved.

WO2024230707A1PCT designated stage expired Publication Date: 2024-11-14SHANGHAI PHARMACEUTICALS HOLDING CO LTD

Patent Information

Application Number
PCT/CN2024/091532
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-24
Filing Date
2024-05-07
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing KRAS G12D mutant protein inhibitors lack effectiveness and are difficult to effectively inhibit the activation of KRAS G12D mutant protein, leading to cancer progression.

Method used

Provide a quinazoline compound to prepare compounds that have good inhibitory effects on the KRAS G12D mutant protein through specific structural design and synthesis routes, including a variety of pharmaceutically acceptable salts, solvates, and stereoisomers. and metabolites.

Benefits of technology

The quinazoline compound significantly inhibits the KRAS G12D mutant protein and has potential prevention and treatment effects in the treatment of cancers caused by KRAS mutations such as blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer and lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024091532_14112024_PF_FP_ABST
    Figure CN2024091532_14112024_PF_FP_ABST
Patent Text Reader

Abstract

A quinazoline compound and a use thereof. The quinazoline compound is shown in formula (I). The quinazoline compound has a good inhibitory effect on a KRAS G12D mutant protein, and has good prospects for drug development.
Need to check novelty before this filing date? Find Prior Art

Description

A quinazoline compound and its application

[0001] This application claims the benefit of Chinese Patent Application No. 2023105042828, filed May 7, 2023, and Chinese Patent Application No. 2023107471391, filed June 24, 2023. This application incorporates the entirety of the aforementioned Chinese patent application. Technical Field

[0002] The present invention relates to a quinazoline compound and application thereof. Background Art

[0003] RAS represents a group of closely related monomeric globular proteins (21 kDa molecular weight) with 189 amino acids that are associated with the plasma membrane and bind GDP or GTP. RAS acts as a molecular switch. When RAS contains bound GDP, it is in a resting or closed position and is "inactive." In response to cell exposure to certain growth-promoting stimuli, RAS is induced to exchange its bound GDP for GTP. When bound to GTP, RAS is "opened" and can interact with and activate other proteins (its "downstream targets"). The RAS protein itself has a very low intrinsic ability to hydrolyze GTP back to GDP, thereby turning itself into a closed state. Turning off RAS requires an exogenous protein called GTPase activating protein (GAP), which interacts with RAS and greatly accelerates the conversion of GTP to GDP. Any mutation in RAS that affects its ability to interact with GAP or convert GTP back to GDP will result in prolonged protein activation, and therefore prolonged signals transmitted to cells telling them to continue growing and dividing. Because these signals cause cell growth and division, overactivated RAS signaling can ultimately lead to cancer.

[0004] Structurally, the RAS protein contains a G domain responsible for the enzymatic activity of RAS - guanine nucleotide binding and hydrolysis (GTPase reaction). It also contains a C-terminal extension called the CAAX box, which can be post-translationally modified and is responsible for targeting the protein to the membrane. The G domain is approximately 21-25 kDa in size and contains a phosphate binding loop (P-loop). The P-loop represents the pocket in the protein that binds nucleotides, and this is the rigid part of the domain with conserved amino acid residues that are necessary for nucleotide binding and hydrolysis (glycine 12, threonine 26, and lysine 16). The G domain also contains the so-called switch I region (residues 30-40) and switch II region (residues 60-76), which are both dynamic parts of the protein and are often referred to as a "spring-loaded" mechanism due to the ability of the dynamic part to switch between a resting and loaded state. The main interaction is the hydrogen bond formed by threonine-35 and glycine-60 with the γ-phosphate of GTP, which enables the switch 1 region and the switch 2 region to maintain their active conformations, respectively. Following hydrolysis of GTP and release of phosphate, both relax into the inactive GDP conformation.

[0005] The most notable members of the RAS subfamily are HRAS, KRAS, and NRAS, which are primarily implicated in many types of cancer. However, there are numerous other members, including DIRAS1; DIRAS2; DIRAS3; ERAS; GEM; MRAS; NKIRAS1; NKIRAS2; NRAS; RALA; RALB; RAP1A; RAP1B; RAP2A; RAP2B; RAP2C; RASD1; RASD2; RASL10A; RASL10B; RASL11A; RASL11B; RASL12; REM1; REM2; RERG; RERGL; RRAD; RRAS, and RRAS2.

[0006] Mutations in any of the three major isoforms of the RAS gene (HRAS, NRAS, or KRAS) are among the most common events in human tumor formation. Approximately 30% of all human tumors were found to carry some mutation in the RAS gene. Notably, KRAS mutations were detected in 25%-30% of tumors. In contrast, the rates of oncogenic mutations in NRAS and HRAS family members were much lower (8% and 3%, respectively). The most common KRAS mutations were found at residues G12 and G13 in the P-loop and at residue Q61. Among tumor-associated KRAS G12 mutations, KRAS G12D had the highest mutation rate, at approximately 40%.

[0007] Given the importance of KRAS aberrant activation in cancer progression and the prevalence of KRAS mutations in human cancers, KRAS has long been a target of interest for drug developers. Despite progress in this area, there remains a need for improved inhibitors of the KRAS G12D mutant protein.

[0008] Summary of the Invention

[0009] The technical problem to be solved by the present invention is to overcome the deficiency of the prior art in the lack of inhibitors for KRAS G12D mutant protein. To this end, a quinazoline compound and its application are provided. The quinazoline compound provided by the present invention has a good inhibitory effect on KRAS G12D mutant protein.

[0010] The present invention solves the above technical problems through the following technical solutions.

[0011] The present invention provides a compound as shown in Formula I, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound:

[0012] Among them, R 1 C6-C 14 The aryl group, one or more R 1-1 Substituted C6~C 14 aryl, 6-14 membered heteroaryl or one or more R 1-2 substituted 6-14 membered heteroaryl, said 6-14 membered heteroaryl and said substituted by one or more R 1-2 The heteroatoms in the substituted 6-14 membered heteroaryl are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0013] R 1-1 and R 1-2 Each is independently hydroxy, C1-C6 alkyl, C3-C8 cycloalkyl, halogen, NH2, CN, -O(C=O)NR 1-a R 1- b 、-OP(=O)(OR 1-c )2、-O(S=O)2-R 1-d , C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl substituted by one or more halogens, C1-C6 alkoxy substituted by one or more halogens or by one or more R 1-e Substituted C3-C8 cycloalkyl,

[0014] R 1-a 、R1-b and R 1-c Each independently represents H or a C1-C6 alkyl group;

[0015] R 1-d Independently by one or more R 1-d-1 Substituted C6~C 14 Aryl; R 1-d-1 independently NO2;

[0016] R 1-e 、R 1-f are independently C1-C6 alkyl;

[0017] R 2 is H, halogen or C1-C3 alkyl;

[0018] R 3 is hydrogen, R 4 is a 7-12 membered bridged heterocyclic alkyl group or "surrounded by one or more R 4-1 substituted 7-12 membered bridged heterocycloalkyl", wherein the heteroatoms in the 7-12 membered bridged heterocycloalkyl are independently one or more of N, O and S, and the number of heteroatoms is 1-3; or R 3 、R 4 Connected to form a 12-16 membered heterocycloalkyl group; the heteroatoms in the 12-16 membered heterocycloalkyl group are independently one or more of N, O and S, and the number of heteroatoms is 1-3;

[0019] R 4-1 is a C1-C6 alkyl group;

[0020] R 5 is a 4-12 membered heterocycloalkyl group or is replaced by one or more R 5-1 substituted 4-12 membered heterocycloalkyl, said 4-12 membered heterocycloalkyl and said 5-1 The heteroatoms in the substituted 4-12 membered heterocycloalkyl group are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0021] R 5-1 are independently hydroxy, C1-C6 alkyl, C6-C 14 Aryl, -O-C6-C 14 Aryl, one or more R 5-1-1 Substituted C1-C6 alkyl, one or more R 5-1-2 Substituted C6-C 14 Aryl or one or more R 5-1-3 Substituted-O-C6-C 14 aryl;

[0022] R 5-1-1is hydroxy, halogen, 4-10 membered heterocycloalkyl or is replaced by one or more R 5-1-1-1a substituted 4-10 membered heterocycloalkyl; said 4-10 membered heterocycloalkyl and said substituted by one or more R 5-1-1-1a The heteroatoms in the substituted 4-10 membered heterocycloalkyl group are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0023] R 5-1-1-1a Independently C6-C 14 Aryl or one or more R a Substituted C6-C 14 aryl;

[0024] R a are independently -C(=O)NH2;

[0025] R 5-1-2 are independently -C(=O)NH2;

[0026] R 5-1-3 are independently C1-C6 alkyl;

[0027] n is 1, 2, or 3;

[0028] A is CR 6 or N;

[0029] R 6 is H, C1-C6 alkyl, cyano, halogen, or C1-C6 alkyl substituted by one or more halogens;

[0030] The compound shown in formula I is not the following compound:

[0031] In a certain embodiment, the compound of Formula I, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound:

[0032] Among them, R 1 C6-C 14 The aryl group, one or more R 1-1 Substituted C6~C 14 aryl, 6-14 membered heteroaryl or one or more R 1-2 substituted 6-14 membered heteroaryl, said 6-14 membered heteroaryl and said substituted by one or more R 1-2 The heteroatoms in the substituted 6-14 membered heteroaryl are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0033] R 1-1and R 1-2 Each is independently hydroxy, C1-C6 alkyl, C3-C8 cycloalkyl, halogen, NH2, CN, -O(C=O)NR 1-a R 1- b 、-OP(=O)(OR 1-c )2、-O(S=O)2-R 1-d , C2-C6-alkynyl, C1-C6 alkoxy, C1-C6 alkyl substituted by one or more halogens, C1-C6 alkoxy substituted by one or more halogens or by one or more R 1-e Substituted C3-C8 cycloalkyl, R 1-a 、R 1-b and R 1-c Each independently represents H or a C1-C6 alkyl group;

[0034] R 1-d Independently by one or more R 1-d-1 Substituted C6~C 14 Aryl; R 1-d-1 independently NO2;

[0035] R 1-e 、R 1-f are independently C1-C6 alkyl;

[0036] R 2 is H, halogen or C1-C3 alkyl;

[0037] R 3 is hydrogen, R 4 is a 7-12 membered bridged heterocyclic alkyl group or "surrounded by one or more R 4-1 substituted 7-12 membered bridged heterocycloalkyl”, wherein the heteroatoms in the 7-12 membered bridged heterocycloalkyl are independently one or more of N, O or S, and the number of heteroatoms is 1-3; or R 3 、R 4 Connected to form a 12-16 membered heterocycloalkyl group;

[0038] R 4-1 is a C1-C6 alkyl group;

[0039] R 5 is a 4-10 membered heterocycloalkyl group or is replaced by one or more R 5-1 substituted 4-10 membered heterocycloalkyl, said 4-10 membered heterocycloalkyl and said 5-1 The heteroatoms in the substituted 4-10 membered heterocycloalkyl group are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3;

[0040] R5-1 is independently C1-C6 alkyl or is replaced by one or more R 5-1-1 Substituted C1-C6 alkyl;

[0041] R 5-1-1 is hydroxy or halogen;

[0042] n is 1, 2, or 3;

[0043] A is CR 6 or N;

[0044] R 6 is H, C1-C6 alkyl, cyano, halogen, or C1-C6 alkyl substituted by one or more halogens;

[0045] The compound shown in formula I is not the following compound:

[0046] In a certain embodiment, the compound represented by Formula I, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, wherein the compound represented by Formula I is represented by Formula I-1, I-2, I-3 or I-4:

[0047] wherein X is N, O or S;

[0048] n1 is independently 1, 2, 3 or 4;

[0049] R 6 、R 7 are independently H, C1-C6 alkyl or halogen.

[0050] In a certain embodiment, the compound as shown in Formula I, I-1, I-2, I-3 or I-4, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite or isotope thereof, the compound as shown in Formula I, I-1, I-2, I-3 or I-4 satisfies one or more of the following conditions:

[0051] (1)R 1 In the above, the C6~C 14 The aryl group or one or more R 1-1 Substituted C6~C 14 The C6~C 14 The aryl groups are independently C6~C 10 The aryl group of

[0052] (2)R 1wherein the 6-14 membered heteroaryl group is or is replaced by one or more R 1-2 The C6-C 14 The heteroaryl groups can be independently C6-C 10 Heteroaryl, for example pyridyl, pyrimidinyl, indolyl, benzoxazolyl, benzimidazolyl, benzopyrazolyl, quinolinyl, isoquinolinyl, benzothiazolyl, pyridopyrazolyl, benzothiophenyl, for example

[0053] (3)R 1-1 wherein the C1-C6 alkyl group substituted by one or more halogens is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as ethyl;

[0054] (4)R 1-1 、R 1-2 wherein the C3-C8 cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, for example, cyclopropyl;

[0055] (5)R 1-1 、R 1-2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example fluorine;

[0056] (6)R 1-1 、R 1-2 In the above, the C2-C6 alkynyl group is a C2-C4 alkynyl group, such as ethynyl;

[0057] (7)R 2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example fluorine;

[0058] (8)R 2 In the above, the C1-C3 alkyl group is methyl, ethyl, n-propyl, or isopropyl;

[0059] (9)R 4 wherein the 7-12 membered bridged heterocyclic alkyl group and the “ 4-1 The 7-12 membered bridged heterocycloalkyl in the "substituted 7-12 membered bridged heterocycloalkyl" is independently an 8-membered bridged heterocycloalkyl or a 9-membered bridged heterocycloalkyl, the heteroatom is N, the number is 2, and may be a bicyclo[3.2.1]octyl group, for example It can also be a bicyclo[4.2.1]nonyl group, for example

[0060] (10)R 3 、R 4In the heterocycloalkyl group formed by connecting 12-16 members, the 12-16 membered heterocycloalkyl group is a 13-membered or 14-membered tricyclic heterocycloalkyl group, the heteroatom is N or O, the number of N is 2, and the number of O is 1, for example

[0061] (11)R 5 wherein the 4-10 membered heterocycloalkyl group is replaced by one or more R 5-1 The 4-10 membered heterocycloalkyl in the substituted 4-10 membered heterocycloalkyl is independently a 5-6 membered monocyclic heterocycloalkyl, wherein the heteroatoms are N and / or O, and the number is 1 or 2; it may also be a piperidinyl, piperazine or morpholinyl, and may further be

[0062] (12)R 5 wherein the 4-10 membered heterocycloalkyl group is replaced by one or more R 5-1 The 4-10 membered heterocycloalkyl in the substituted 4-10 membered heterocycloalkyl is independently an 8-membered bridged heterocycloalkyl or a 9-membered bridged heterocycloalkyl, and the heteroatoms are N and / or O, and the number is 1 or 2, for example

[0063] (13)R 5-1 wherein the C1-C6 alkyl group is replaced by one or more R 5-1-1 The C1-C6 alkyl group in the substituted C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl;

[0064] (14)n is 1.

[0065] In one scenario, R 1 wherein the 6-14 membered heteroaryl group is or is replaced by one or more R 1-2 The C6-C 14 The heteroaryl groups can be independently C6-C 10 Heteroaryl, for example pyridyl, pyrimidinyl, indolyl, benzoxazolyl, benzimidazolyl, benzopyrazolyl, quinolinyl, isoquinolinyl, benzothiazolyl, pyridopyrazolyl, benzothiophenyl, for example

[0066] In one scenario, R 5 wherein the 4-12 membered heterocycloalkyl group is replaced by one or more R 5-1 The 4-12-membered heterocycloalkyl in the substituted 4-12-membered heterocycloalkyl is independently a 4-10-membered heterocycloalkyl; preferably a 5-6-membered monocyclic heterocycloalkyl, wherein the heteroatoms are N and / or O, and the number is 1 or 2; it may also be a piperidinyl, piperazine or morpholinyl, and may further be

[0067] In one scenario, R 5 wherein the 4-12 membered heterocycloalkyl group is replaced by one or more R 5-1 The 4-12-membered heterocycloalkyl in the substituted 4-12-membered heterocycloalkyl is independently an 8-membered bridged heterocycloalkyl, a 9-membered bridged heterocycloalkyl, a 9-membered spiro heterocycloalkyl or an 11-membered spiro heterocycloalkyl, and the heteroatoms are N and / or O, and the number is 1 or 2; for example Another example is

[0068] In one scenario, R 5-1 In the C6-C 14 Aryl, -O-C6-C 14 C6-C in aromatic groups 14 Aryl, one or more R 5- 1-2 Substituted C6-C 14 C6-C in aromatic groups 14 The aryl group and one or more R 5-1-3 Substituted-O-C6-C 14 C6-C in aromatic groups 14 The aryl groups are independently C6-C 10 The aryl group is, for example, phenyl or naphthyl, preferably phenyl.

[0069] In one scenario, R 5-1-1 wherein the 4-10 membered heterocycloalkyl group and one or more R 5-1-1-1a The 4-10 membered heterocycloalkyl in the substituted 4-10 membered heterocycloalkyl is independently a 5-6 membered monocyclic heterocycloalkyl, wherein the heteroatoms are N and / or O, and the number is 1 or 2; it may also be a piperidinyl, piperazine or morpholinyl, and may further be

[0070] In one scenario, R 5-1-1-1a In the C6-C 14 The aryl group and one or more R a Substituted C6-C 14 C6-C in aromatic groups 14 The aryl groups are independently C6-C 10 The aryl group is, for example, phenyl or naphthyl, preferably phenyl.

[0071] In one scenario, R 5-1-3 In the above, the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, isopropyl.

[0072] In a certain embodiment, the compound as shown in Formula I, I-1, I-2, I-3 or I-4, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite or isotope thereof, the compound as shown in Formula I, I-1, I-2, I-3 or I-4 satisfies one or more of the following conditions:

[0073] (1)R 1-1 In, the C1-C6 alkyl group is ethyl;

[0074] (2)R 1-1 wherein the C3-C8 cycloalkyl group is a cyclopropyl group;

[0075] (3)R 1-1 wherein the halogen is fluorine or chlorine;

[0076] (4)R 1-1 wherein the C2-C6 alkynyl group is an ethynyl group;

[0077] (5)R 1-2 In, the C1-C6 alkyl group is a methyl group;

[0078] (6)R 1-2 In the formula (a), the C1-C6 alkyl group substituted by one or more halogens is trifluoromethyl;

[0079] (7)R 2 wherein the halogen is fluorine;

[0080] (8)R 4 wherein the 7-12 membered bridged heterocyclic alkyl group and the “ 4-1 The 7-12 membered bridged heterocycloalkyl in the "substituted 7-12 membered bridged heterocycloalkyl" is

[0081] (9)R 3 、R 4 Connected to form a 12-16 membered heterocycloalkyl, the 12-16 membered heterocycloalkyl is

[0082] (10)R 5 wherein the 4-10 membered heterocycloalkyl group is By one or more R 5-1 The substituted 4-10 membered heterocycloalkyl group is

[0083] (11)R 5 wherein the 4-10 membered heterocycloalkyl group is replaced by one or more R 5-1The 4-10 membered heterocycloalkyl in the substituted 4-10 membered heterocycloalkyl is independently an 8-membered bridged heterocycloalkyl or a 9-membered bridged heterocycloalkyl, and the heteroatoms are N and / or O, and the number is 1 or 2, for example

[0084] (12)n is 1.

[0085] In one scenario, R 5 wherein the 4-12 membered heterocycloalkyl group is By one or more R 5-1 The substituted 4-12 membered heterocycloalkyl group is

[0086] In one scenario, R 5 wherein the 4-12 membered heterocycloalkyl group is replaced by one or more R 5-1 The 4-12 membered heterocycloalkyl in the substituted 4-12 membered heterocycloalkyl is independently an 8-membered bridged heterocycloalkyl, a 9-membered bridged heterocycloalkyl, a 9-membered spiro heterocycloalkyl or an 11-membered spiro heterocycloalkyl, and the heteroatoms are N and / or O, and the number is 1 or 2, for example

[0087] In one embodiment, the pharmaceutically acceptable salt of the compound of Formula I may be a hydrochloride or a formate salt.

[0088] In a certain embodiment, the compound as shown in Formula I, I-1, I-2, I-3 or I-4, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite or isotope thereof, the compound as shown in Formula I, I-1, I-2, I-3 or I-4 satisfies one or more of the following conditions:

[0089] (1) R 1 for

[0090] (2) R2 is fluorine;

[0091] (3) R3 is hydrogen;

[0092] (4)R 4 for

[0093] (5)R 5 for

[0094] (6)n is 1.

[0095] In one embodiment, the R 1 for

[0096] In one scenario, R 5 for

[0097] In a certain embodiment, the compound represented by Formula I, I-1 or I-3, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite or isotope thereof, wherein the compound represented by Formula I, I-1 and I-3 satisfies the following conditions:

[0098] (1) R 1 for

[0099] (2) R2 is fluorine;

[0100] (3) R3 is hydrogen;

[0101] (4)R 4 for

[0102] (5)R 5 for

[0103] (6)n is 1.

[0104] In a certain embodiment, the compound represented by Formula I, I-1 or I-3, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite or isotope thereof, and the compound represented by Formula I, I-3 or I-4 meet the following conditions:

[0105] (1) R 1 for

[0106] (2) R2 is fluorine;

[0107] (3) R3 is hydrogen;

[0108] (4)R 4 for

[0109] (5)R5 for

[0110] (6)n is 1.

[0111] In a certain embodiment, the compound as shown in Formula I, I-2, or I-4, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite, or isotope thereof, wherein the compound as shown in Formula I, I-2, or I-4 satisfies the following conditions:

[0112] (1) R 1 for

[0113] (2) R2 is fluorine;

[0114] (3)R 3 、R 4 Connected to form a 12-16 membered heterocycloalkyl, the 12-16 membered heterocycloalkyl is

[0115] (5)R 5 for

[0116] (6) R6 is hydrogen;

[0117] (7) R7 is hydrogen;

[0118] (8) n1 is 1 or 2;

[0119] (9)n is 1.

[0120] In a certain embodiment, the compound represented by Formula I, I-1, I-2, I-3 or I-4, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite or isotope thereof, the compound represented by Formula I, I-1, I-2, I-3 or I-4 is any of the following compounds:

[0121] In one embodiment, the "*" in the above compound indicates a chemical bond with a stereo configuration. Any one of .

[0122] In addition, the present invention provides a compound 16 or 16-a or a pharmaceutically acceptable salt thereof, the structural formula of which is shown below:

[0123] In one embodiment, the pharmaceutically acceptable salt of the compound of Formula I is any of the following compounds:

[0124] The compounds of the present invention, such as those shown in Formula I, I-1, I-2, I-3, I-4, 16 or 16-a, their pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, prodrugs, metabolites or isotopic compounds thereof, can be synthesized by methods similar to those known in the chemical field, and the steps and conditions thereof can be referenced to the steps and conditions of similar reactions in the art, in particular, according to the description herein. The starting materials are generally obtained from commercial sources, such as Aldrich, or can be readily prepared using methods known to those skilled in the art (obtained through SciFinder, Reaxys online database).

[0125] The present invention provides a pharmaceutical composition comprising the above-mentioned compound as shown in Formula I, I-1, I-2, I-3, I-4, 16 or 16-a, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound.

[0126] The present invention provides a pharmaceutical composition comprising a substance X and a pharmaceutical excipient;

[0127] The substance X is the compound shown in the above formula I, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound,

[0128] Alternatively, the above-mentioned compound 16 or 16-a, or a pharmaceutically acceptable salt thereof.

[0129] In the pharmaceutical composition, the amount of the compound shown in Formula I, I-1, I-2, I-3, I-4, 16 or 16-a, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound can be a therapeutically effective amount.

[0130] The present invention also provides the use of the above-mentioned compound as shown in Formula I, I-1, I-2, I-3, I-4, 16 or 16-a, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite, isotope compound or the above-mentioned pharmaceutical composition in the preparation of KRAS mutant protein inhibitors.

[0131] The present invention also provides a use of the substance X or the pharmaceutical composition in the preparation of a KRAS mutant protein inhibitor.

[0132] In the application, the KRAS mutant protein may be a KRAS G12D mutant protein; the KRAS mutant protein inhibitor is used in vitro, mainly for experimental purposes, for example: as a standard sample or control sample for comparison, or prepared according to conventional methods in the art to provide a kit for rapid detection of the effect of the KRAS G12D mutant protein inhibitor.

[0133] The present invention also provides the use of the above-mentioned compound as shown in Formula I, I-1, I-2, I-3, I-4, 16 or 16-a, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite, isotope compound or the above-mentioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to prevent or treat cancer mediated by KRAS mutation.

[0134] The present invention also provides a use of the substance X or the pharmaceutical composition in preparing a drug, wherein the drug is used to prevent or treat cancer mediated by KRAS mutation.

[0135] The KRAS mutant protein is preferably a KRAS G12D mutant protein.

[0136] The cancer mediated by KRAS mutant protein can be blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer or lung cancer, etc.

[0137] The present invention also provides the use of the above-mentioned compound as shown in Formula I, I-1, I-2, I-3, I-4, 16 or 16-a, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite, its isotope compound or the above-mentioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to prevent or treat cancer.

[0138] The present invention also provides a use of the above-mentioned substance X or the above-mentioned pharmaceutical composition in the preparation of a drug, wherein the drug is used to prevent or treat cancer.

[0139] The cancers include, for example, blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer or lung cancer.

[0140] The cancer is a cancer mediated by KRAS mutation. The KRAS mutant protein may be a KRAS G12D mutant protein. The present invention also provides a method for treating, preventing or treating cancer mediated by KRAS mutation, comprising administering to a patient

[0141] A therapeutically effective amount of the compound of formula I, its pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, prodrug, metabolite, isotope or pharmaceutical composition.

[0142] The cancers include, for example, blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer or lung cancer.

[0143] The KRAS mutant protein may be a KRAS G12D mutant protein.

[0144] The present invention also provides a method for treating, preventing or treating cancer, which comprises administering to a patient a therapeutically effective amount of the above-mentioned compound as shown in Formula I, I-1, I-2, I-3 or I-4, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite, its isotope compound or the above-mentioned pharmaceutical composition.

[0145] The cancers include, for example, blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer or lung cancer.

[0146] The present disclosure also relates to a method for treating a hyperproliferative disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.

[0147] Ras mutations, including but not limited to K-Ras, H-Ras or N-Ras mutations, have been identified in hematological cancers or malignancies (e.g., cancers affecting the blood, bone marrow and / or lymph nodes). Accordingly, certain embodiments relate to administering a disclosed compound (e.g., in the form of a pharmaceutical composition) to a patient in need of treatment for a hematological cancer or malignancy.

[0148] In certain specific embodiments, the present disclosure relates to methods for treating lung cancer, comprising administering an effective amount of any of the above-described compounds (or pharmaceutical compositions comprising the compounds) to a subject in need thereof.

[0149] In the present invention, the cancer or malignancy includes, but is not limited to, leukemia and lymphoma. In certain embodiments, the blood disease is further exemplified by acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), acute monocytic leukemia (AMoL), and / or other leukemias. In certain embodiments, the lymphoma is exemplified by all subtypes of Hodgkin's lymphoma or non-Hodgkin's lymphoma.

[0150] In certain embodiments of the present invention, the lung cancer is non-small cell lung cancer (NSCLC), such as adenocarcinoma, squamous cell lung cancer, or large cell lung cancer. In other embodiments, the lung cancer is small cell lung cancer. Other lung cancers include, but are not limited to, adenomas, carcinoids, and undifferentiated carcinomas.

[0151] In some embodiments of the present invention, the cancer, such as acute myeloid leukemia, juvenile cancer, childhood adrenocortical carcinoma, AIDS-related cancers (such as lymphoma and Kaposi's sarcoma), anal cancer, appendix cancer, astrocytoma, atypical malformation, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt lymphoma, carcinoid, atypical malformation, embryonal tumor, germ cell tumor, primary lymphoma, cervical cancer, childhood cancer, chordoma, heart tumor, chronic lymphocytic leukemia (CLL), chronic Myelocytic leukemia (CML), chronic myeloproliferative disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, extrahepatic ductal carcinoma in situ (DCIS), embryonal tumors, central nervous system cancer, endometrial cancer, ependymoma, esophageal cancer, granulomatous neuroblastoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, gastric cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, heart disease, liver cancer, Hodgkin lymphoma, hypopharyngeal carcinoma carcinoma, intraocular melanoma, pancreatic islet cell tumor, pancreatic neuroendocrine tumor, kidney cancer, laryngeal cancer, lip and oral cancer, liver cancer, lobular carcinoma in situ (LCIS), lung cancer, lymphoma, metastatic squamous cell carcinoma, occult primary, midline cancer, oral cancer, multiple endocrine neoplasms syndrome, multiple myeloma / plasmacytoma, fungal infections, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasms, multiple myeloma, Merkel cell carcinoma, malignant mesothelioma, malignant fibrous histiocytoma of the bone and osteosarcoma, nasal cavity and paranasal sinuses, nasal and paranasal sinus neuroblastoma, non-Hodgkin's disease Lymphoma, non-small cell lung cancer (NSCLC), oral cavity cancer, lip and oral cavity cancer, oropharyngeal cancer, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach (gastric) cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-cell lymphoma, testicular cancer, laryngeal cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumor, uncommon childhood cancers, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or viral cancer. In some embodiments, the non-cancerous hyperproliferative disorder is, for example, a benign hyperplasia of the skin (eg, psoriasis), restenosis, or the prostate (eg, benign prostatic hypertrophy (BPH)).

[0152] Definition of terms

[0153] The term "pharmaceutically acceptable" means that salts, solvents, excipients, etc. are generally non-toxic, safe, and suitable for use by patients. The "patient" is preferably a mammal, more preferably a human.

[0154] The term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt as defined herein and having all the effects of the parent compound. Pharmaceutically acceptable salts can be prepared by adding the corresponding acid in a suitable organic solvent for an organic base and treating according to conventional methods.

[0155] Examples of salt formation include: For base addition salts, it is possible to prepare alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., aluminum, magnesium, calcium, zinc or bismuth) salts by treating a compound of the invention having an appropriate acidic proton with an alkali metal or alkaline earth metal hydroxide or alkoxide (e.g., ethanolate or methanolate) or a suitable basic organic amine (e.g., diethanolamine, choline or meglumine) in an aqueous medium.

[0156] Alternatively, for acid addition salts, salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; and salts formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, oxalic acid, pyruvic acid, malonic acid, mandelic acid, methanesulfonic acid, mucofuric acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, citric acid, cinnamic acid, p-toluenesulfonic acid or trimethylacetic acid.

[0157] The term "solvate" refers to a compound of the present invention combined with a stoichiometric or non-stoichiometric solvent. The solvent molecules in the solvate may be present in an ordered or non-ordered arrangement. Such solvents include, but are not limited to, water, methanol, and ethanol.

[0158] The term "prodrug" refers to a compound that is obtained by chemically modifying a drug so that it is inactive or has low activity in vitro and releases the active drug through enzymatic or non-enzymatic conversion in vivo to exert its pharmacological effect.

[0159] The term "metabolite" refers to intermediate and terminal metabolites in metabolism.

[0160] The term "isotopic compound" refers to a compound in which one or more atoms may exist in a form other than their natural abundance. For example, in the case of hydrogen atoms, their non-natural abundance means that about 95% of them are deuterium.

[0161] The term "pharmaceutical excipient" may refer to those excipients widely used in the field of pharmaceutical production. Excipients are primarily used to provide a safe, stable, and functional pharmaceutical composition. They may also provide methods to dissolve the active ingredient at a desired rate after administration to a subject, or to promote effective absorption of the active ingredient after administration of the composition to a subject. The pharmaceutical excipients may be inert fillers, or may provide a function, such as stabilizing the overall pH value of the composition or preventing degradation of the active ingredient in the composition. The pharmaceutical excipients may include one or more of the following excipients: binders, suspending agents, emulsifiers, diluents, fillers, granulating agents, adhesives, disintegrants, lubricants, anti-adhesive agents, glidants, wetting agents, gelling agents, absorption delaying agents, dissolution inhibitors, enhancers, adsorbents, buffers, chelating agents, preservatives, colorants, flavoring agents, and sweeteners.

[0162] The pharmaceutical compositions of the present invention can be prepared according to the disclosed content using any method known to those skilled in the art, such as conventional mixing, dissolving, granulating, emulsifying, grinding, encapsulating, embedding or lyophilizing processes.

[0163] The pharmaceutical compositions of the present invention can be administered in any form, including injection (intravenous), mucosal, oral (solid and liquid preparations), inhalation, ophthalmic, rectal, topical or parenteral (infusion, injection, implantation, subcutaneous, intravenous, intraarterial, intramuscular) administration. The pharmaceutical compositions of the present invention can also be controlled-release or delayed-release dosage forms (e.g., liposomes or microspheres). Examples of solid oral formulations include, but are not limited to, powders, capsules, caplets, soft capsules, and tablets. Examples of liquid formulations for oral or mucosal administration include, but are not limited to, suspensions, emulsions, elixirs, and solutions. Examples of topical formulations include, but are not limited to, emulsions, gels, ointments, creams, patches, pastes, foams, lotions, drops, or serum preparations. Examples of formulations for parenteral administration include, but are not limited to, solutions for injection, dry preparations that can be dissolved or suspended in a pharmaceutically acceptable carrier, suspensions for injection, and emulsions for injection. Examples of other suitable formulations of the pharmaceutical composition include, but are not limited to, eye drops and other ophthalmic preparations; aerosols such as nasal sprays or inhalers; liquid dosage forms suitable for parenteral administration; suppositories; and lozenges.

[0164] "Treatment" means any treatment of a disease in a mammal, including: (1) preventing the disease, i.e., causing clinical symptoms of the disease not to develop; (2) inhibiting the disease, i.e., preventing the development of clinical symptoms; (3) alleviating the disease, i.e., causing the regression of clinical symptoms.

[0165] "Effective amount" means an amount sufficient, when the compound is administered to a patient in need of treatment, to (i) treat the disease of interest, (ii) reduce, ameliorate, or eliminate one or more symptoms of a particular disease or condition, or (iii) delay the onset of one or more symptoms of a particular disease or condition as described herein. The amount of the carbonyl heterocyclic compound of Formula II or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described above, corresponding to this amount, will vary depending on factors such as the specific compound, the disease condition and its severity, the characteristics of the patient in need of treatment (e.g., body weight), but can nonetheless be routinely determined by those skilled in the art.

[0166] As used herein, "prevention" refers to a reduction in the risk of acquiring or developing a disease or disorder.

[0167] The term "alkyl" refers to a straight or branched chain alkyl group having the specified number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Unless otherwise specified, an alkyl group is unsubstituted.

[0168] The term "heterocycloalkyl" means a stable 3- to 16-membered saturated cyclic group consisting of 2-20 carbon atoms and 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur. Unless otherwise specified in the specification, a heterocycloalkyl group can be monocyclic ("monocyclic heterocycloalkyl"), or a bicyclic, tricyclic, or higher ring system, which can include fused (fused ring), bridged (bridged ring), or spiro (spirocyclic) ring systems (e.g., bicyclic systems ("bicyclic heterocycloalkyl"). Heterocycloalkyl bicyclic ring systems can include one or more heteroatoms in one or both rings; and are saturated. Unless otherwise specified, heterocycloalkyl groups are unsubstituted.

[0169] The term "aryl" refers to phenyl or naphthyl.

[0170] The term "heteroaryl" refers to an aromatic group containing heteroatoms, preferably an aromatic 4-10 membered monocyclic or 5-10 membered bicyclic ring containing 1, 2 or 3 groups independently selected from nitrogen, oxygen and sulfur, such as furanyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, diazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, benzimidazolyl, indolyl, indazolyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, quinolyl, isoquinolyl and the like.

[0171] When the structural formula of the group described in the present invention is a polycyclic structure, for example Unless otherwise specified, Indicates that the substitution site can be Any substitutable position on the two rings (e.g. ), It is connected to other fragments and groups in the compound through any substitutable site.

[0172] It will be understood by those skilled in the art that the structural formulas used in the present invention to describe groups are based on the conventions used in the art. It means that the corresponding group is connected to other fragments and groups in the compound through this site.

[0173] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.

[0174] The positive improvement effect of the present invention is that the compound of the present invention has a good inhibitory effect on KRAS G12D mutant protein. DETAILED DESCRIPTION

[0175] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples.

[0176] Preparation Example 1: Synthesis of 320-6

[0177] Step 1:

[0178] To a solution of 2-chloro-3-fluoro-4-aminopyridine (1 g, 6.82 mmol, 1.0 eq) in acetonitrile (10 ml) was added N-iodosuccinimide (1.84 g, 7.77 mmol, 1.2 eq) and p-toluenesulfonic acid (130 mg, 0.65 mmol, 0.1 eq) under stirring at 25 degrees Celsius. The mixture was reacted at 70 degrees Celsius for 16 hours. The reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction, the mixture was cooled to 25 degrees Celsius, diluted with 30 ml of water, extracted with ethyl acetate (50 ml x 3), and the organic phases were combined. The organic phases were washed sequentially with 50 ml of saturated sodium carbonate solution, 50 ml of saturated sodium sulfite solution, and 50 ml of saturated brine. The washed organic phase was then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 45% ethyl acetate / petroleum ether. The resulting fraction was evaporated to remove the solvent under reduced pressure to afford compound 320-1 (yellow solid, 1.72 g, 95% yield). MS (ESI, m / z): 272.9 / 274.9 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.17 (s, 1H), 4.84 (s, 2H).

[0179] Step 2:

[0180] To a solution of compound 320-1 (1 g, 3.67 mmol, 1.0 equiv) in ethanol (10 mL) was added triethylamine (1.38 g, 12.96 mmol, 3.6 equiv) and dichlorobis(triphenylphosphine)palladium (266 mg, 0.36 mmol, 0.1 equiv) at 25°C under nitrogen and stirring. The mixture was reacted at 80°C for 15 hours under a carbon monoxide atmosphere (3 atm). The reaction progress was monitored by liquid chromatography-mass spectrometry. After completion of the reaction, the reaction solution was cooled to 25°C, filtered through celite, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 31% ethyl acetate / petroleum ether. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 320-2 (yellow solid, 660 mg, 74% yield). MS (ESI, m / z): 219.3 / 221.3 [M+H] + ; 1 H NMR (300MHz, CDCl3) δ8.56 (s, 1H), 4.41 (q, J = 7.1Hz, 2H), 1.43 (t, J = 7.1, 3H).

[0181] Step 3:

[0182] Under nitrogen protection and stirring at 25 degrees Celsius, trichloroacetyl isocyanate (853 mg, 4.30 mmol, 1.5 eq) was added dropwise to a solution of compound 320-2 (660 mg, 2.87 mmol, 1.0 eq) in tetrahydrofuran (6 ml). The mixture was reacted at 25 degrees Celsius for 20 minutes, and the reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction, the reaction solution was concentrated to obtain a crude product. The obtained crude product was slurried with 10 ml of methyl tert-butyl ether, filtered, and the filter cake was washed with methyl tert-butyl ether (2 ml x 3). The filter cake was dried to obtain compound 320-3 (white solid, 1.0 g, yield 77%). MS (ESI, m / z): 406.0 / 408.0 / 410.0 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ11.19 (s, 1H), 8.91 (s, 1H), 8.78 (d, J = 0.8Hz, 1H), 4.48 (q, J = 7.1Hz, 2H), 1.43 (t, J = 7.1, 3H).

[0183] Step 4:

[0184] Under stirring at 25 degrees Celsius, ammonia methanol solution (7 mol / L, 1 ml) was added dropwise to a solution of compound 320-3 (1 g, 2.334 mmol, 1.00 eq) in methanol (10 ml). The mixture was reacted at 25 degrees Celsius for 1 hour. The reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction, the reaction solution was concentrated to obtain a crude product. The crude product was slurried with 10 ml of methyl tert-butyl ether, filtered, and the filter cake was washed with methyl tert-butyl ether (2 ml x 3). The filter cake was dried to obtain compound 320-4 (white solid, 594 mg, 94% yield). MS (ESI, m / z): 216.1 / 218.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.34 (d, J=1.2Hz, 1H).

[0185] Step 5:

[0186] Under nitrogen protection at zero degrees Celsius, compound 320-4 (500 mg, 2.20 mmol, 1.0 equiv), phosphorus oxychloride (9 ml), and N,N-diisopropylethylamine (0.9 ml) were added sequentially to a dry 100 ml single-necked flask. The mixture was stirred at zero degrees Celsius for 10 minutes, then transferred to a 90 degrees Celsius oil bath and refluxed for 12 hours. The reaction process was monitored by liquid chromatography-mass spectrometry. After the reaction was completed, the reaction solution was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 30% ethyl acetate / petroleum ether. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 320-5 (yellow solid, 425 mg, 72% yield).

[0187] Step 6:

[0188] Compound 320-5 (425 mg, 1.68 mmol, 1.0 equiv) was dissolved in dichloromethane (5 mL) under nitrogen and stirred at 25°C. N,N-diisopropylethylamine (652 mg, 4.80 mmol, 3.0 equiv) and tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (357 mg, 1.60 mmol, 1.0 equiv) were added sequentially to the solution. The mixture was then allowed to react at 25°C for 1 hour, monitored by liquid chromatography-mass spectrometry. After completion of the reaction, the reaction solution was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 30% ethyl acetate / dichloromethane. The resulting fraction was then evaporated to remove the solvent, yielding compound 320-6 (yellow solid, 700 mg, 97% yield). MS (ESI, m / z): 428.2 / 430.2 [M+H] +; 1 H NMR (300MHz, CDCl3) δ8.86(d,J=0.6Hz,1H),4.59–4.41(m,4H),3.78–3.71(m,2H),2.04–1.96(m,2H),1.75–1.65(m,2H),1.54(s,9H).

[0189] Example 1: Synthesis of Compound 1

[0190] The synthetic route is as follows:

[0191] Step 1: ((2R,6R,7aS)-7a-(((tert-Butyldiphenylsilyl)oxy)methyl)-6-fluoro-3-oxohexahydro-1H-pyrrolizin-2-yl)methyl-4-methylbenzenesulfonate (1-2)

[0192] Under nitrogen protection and stirring at 25°C, compound 1-1 (2 g, 4.52 mmol), TsCl (1.04 g, 5.43 mmol), DIEA (917 mg, 9.06 mmol), DMAP (83 mg, 0.68 mmol), and dichloromethane (20 mL) were added to the reaction flask in sequence. The reaction solution was stirred at 15°C for 16 hours. The reaction solution was concentrated to obtain a crude product, which was purified by column chromatography (petroleum ether / ethyl acetate = 0-30%) to obtain compound 1-2 (colorless oil, 2.8 g, yield 100%). LC-MS: m / z: (M+H) + = 596.0.

[0193] Step 2: (2R,6R,7aS)-2-(((1R,5S)-8-oxo-3-azabicyclo[3.2.1]oct-3-yl)methyl)-7a-((tert-butyldiphenylsilyl)oxy)methyl]-6-fluorohexahydro-3H-pyrrolizin-3-one (1-4)

[0194] Compound 1-2 (1.7 g, 2.9 mmol) and compound 1-3 (650 mg, 5.7 mmol) were dissolved in acetonitrile (25 mL) and potassium carbonate (1.6 g, 8.6 mmol) was added. The reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was filtered and concentrated to obtain a crude product, which was purified by column chromatography (petroleum ether / ethyl acetate = 0-100%) to obtain 1-4 as a white solid (1.15 g, yield 75.5%). LC-MS: m / z: (M+H)+ = 537.0.

[0195] Step 3: ((2R,6R,7aS)-2-(((1R,5S)-8-oxo-3-azabicyclo[3.2.1]oct-3-yl)methyl)-6-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (1-5)

[0196] Compound 1-4 (1.7 g, 3.2 mmol) was dissolved in tetrahydrofuran (20 mL) under nitrogen and stirred at 25°C. LiAlH4 tetrahydrofuran solution (4.8 mL, 1 M, 4.8 mmol) was slowly added dropwise. The reaction mixture was stirred at 60°C for 2 hours. The reaction mixture was cooled to 0°C and quenched by the addition of water (4 mL) and 15% NaOH solution (3 mL). The reaction mixture was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-20%) to obtain compound 1-5 (white solid, 750 mg, 83% yield). MS (ESI, m / z): 285.0 [M+H]+.

[0197] Step 4: Tert-butyl (1R,5S)-3-(2-(((2R,6R,7aS)-2-((8-oxa-3-azabicyclo[3.2.1]oct-3-yl)methyl)-6-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-7-chloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1-7)

[0198] Compound 1-5 (400 mg, 1.4 mmol), compound 320-6 (723 mg, 1.69 mmol), and DIEA (454 mg, 3.51 mmol) were dissolved in dioxane (6 mL) under nitrogen and stirred at 25°C. The mixture was stirred at 100°C for 72 hours. The reaction mixture was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-5%) to obtain compound 1-7 (white solid, 400 mg, 42% yield). MS (ESI, m / z): 676.0 [M+H]+.

[0199] Step 5: (1-9)

[0200] Compound 1-7 (150 mg, 0.22 mmol), compound 1-8 (125 mg, 0.24 mmol), K3PO4 (141 mg, 0.67 mmol), and Ad2nBuP-Pd-G3 (16 mg, 0.22 mmol) were dissolved in tetrahydrofuran (1 mL) under nitrogen at 25°C. The reaction mixture was stirred at 60°C under nitrogen for 3 hours. The reaction mixture was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-5%) to obtain compound 1-9 (brown solid, 150 mg, 65.89% yield). MS (ESI, m / z): 1026.0 [M+H]+.

[0201] Step 6: (1-10)

[0202] Compound 1-9 (150 mg, 0.15 mmol) was dissolved in DMF (1 mL) under nitrogen and stirred at 25°C. CsF (222 mg, 1.46 mmol) was added. The reaction mixture was stirred at 25°C for 1 hour, diluted with water (10 mL), and extracted with ethyl acetate (10 mL x 2). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (methanol / dichloromethane = 0-5%) to obtain compound 1-10 (brown solid, 110 mg, 86.57% yield). MS (ESI, m / z): 870.0 [M+H]+.

[0203] Step 7: (Compound 1)

[0204] Compound 1-10 (100 mg, 0.11 mmol) was dissolved in acetonitrile (1 mL) at 0°C, and a 4M hydrochloric acid solution in dioxane (1 mL) was added. The reaction mixture was stirred at 0°C for 1 hour, concentrated, diluted with water (10 mL), and neutralized to pH 8 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative HPLC to afford the formate salt of compound 1 (yellow solid, 30 mg, 35.96% yield). MS (ESI, m / z): 726.0 [M+H]+.

[0205] 1H NMR(400MHz,MeOD)δ9.08(s,1H),8.48(s,1H),7.89(dd,J=9.1,5.7Hz,1H),7.43–7.30(m,2H),7.23(d,J=2.2Hz,1H),5.48(d,J=52.1Hz,1H),4. 77(dd,J=21.2,11.3Hz,2H),4.52(s,2H),4.24(s,2H),4.08(s,2H),3.9 1(d,J=11.6Hz,2H),3.76–3.65(m,1H),3.65–3.44(m,2H),3.38(s,1H),

[0206] 2.98(t,J=10.9Hz,1H),2.82–2.57(m,3H),2.53–2.23(m,7H),2.14–1.75(m,9H).

[0207] Example 2

[0208] The synthetic route of compound 2 is as follows:

[0209] Step 1: (Compound 2-3)

[0210] Compound 1-7 (180 mg, 0.27 mmol), compound 2-2 (100 mg, 0.29 mmol), K3PO4 (169 mg, 0.80 mmol), and Ad2nBuP-Pd-G3 (19 mg, 0.27 mmol) were dissolved in tetrahydrofuran (2 mL) at 25°C with stirring under nitrogen. The reaction mixture was stirred at 60°C under nitrogen for 3 hours. The reaction mixture was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-5%) to obtain compound 2-3 (brown solid, 110 mg, 48.27% yield). MS (ESI, m / z): 856.0 [M+H]+.

[0211] Step 2: (Compound 2)

[0212] Compound 2-3 (100 mg, 0.12 mmol) was dissolved in acetonitrile (2 mL) at 0°C, and a 4 M hydrochloric acid solution in dioxane (2 mL) was added. The reaction mixture was stirred at 0°C for 1 hour, concentrated, diluted with water (10 mL), and neutralized to pH 8 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative HPLC to afford the formate salt of compound 2 (white solid, 50 mg, 60.13% yield). MS (ESI, m / z): 712.0 [M+H]+.

[0213] 1H NMR(400MHz,MeOD)δ9.11(s,1H),8.49(s,1H),7.65(d,J=7.5Hz,1H),7.42–7.35(m,1H),7.32(d,J=2.6Hz,1H),7 .19(d,J=6.9Hz,1H),7.02(d,J=2.6Hz,1H),5.44(d,J=52.9Hz,1H),4.80–4.66(m,2H),4.46(d,J=10.6Hz,2H),4. 24(s,2H),4.00(d,J=9.1Hz,2H),3.86(ddd,J=18.5,13.3,5.6Hz,2H),3.65–3.58(m,1H),3.56–3.36(m,2H),2.9 9–2.88(m,1H),2.65(dd,J=27.2,10.9Hz,3H),2.53–2.16(m,8H),2.12–1.72(m,9H),0.91(td,J=7.4,1.2Hz,3H).

[0214] Example 3

[0215] The synthetic route of compound 3 is as follows:

[0216] Step 1: Synthesis of (2R,6R,7aS)-7a-((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-2-(hydroxymethyl)hexahydro-3H-pyrrolizin-3-one

[0217] (6R,7aS)-7a-(((tert-Butyldiphenylsilyl)oxy)methyl)-6-fluorohexahydro-3H-pyrrolazin-3-one) (20 g, 48.6 mmol) and hexamethylphosphoric triamide (26 ml) were added to 200 ml of tetrahydrofuran under nitrogen. Lithium diisopropylamide (38 ml, 76 mmol) was then added at -78°C and stirred at this temperature for 0.5 h. Paraformaldehyde (5 g) was then added, and the temperature was gradually warmed to room temperature and stirred for 3 h. The reaction solution was quenched with saturated ammonium chloride and extracted with ethyl acetate (2 x 100 ml). The organic layer was dried over sodium sulfate and concentrated to obtain the crude product, which was purified by column chromatography (ethyl acetate:dichloromethane = 0-50%) to afford compound 3-1 (5 g, colorless liquid, 23% yield). LC-MS: m / z: (M+H)+ = 442.3.

[0218] Step 2: Synthesis of ((2R,6R,7aS)-7a-((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-3-oxohexahydro-1H-pyrrolizin-2-yl)methyl-4-methylbenzenesulfonate

[0219] (2R,6R,7aS)-7a-((tert-Butyldiphenylsilyl)oxy)methyl)-6-fluoro-2-(hydroxymethyl)hexahydro-3H-pyrrolizin-3-one (4.2 g, 9.5 mmol), triethylamine (2.8 ml, 20 mmol), and 4-dimethylaminopyridine (200 mg, 1.6 mmol) were added to 35 ml of dichloromethane, followed by p-toluenesulfonyl chloride (2.78 mg, 14.6 mmol). The mixture was stirred at room temperature overnight. The reaction solution was concentrated, and a mixture consisting of 50 ml of ethyl acetate and 50 ml of petroleum ether was added. The resulting solid was filtered off, and the filtrate was concentrated to afford crude compound 3-2 (5.6 g of a colorless oil, used directly in the next step, yield 99%). LC-MS: m / z: (M+H)+ = 596.2.

[0220] Step 3: Synthesis of (2R,6R,7aS)-7a-((tert-butyldiphenylsilyl)oxy)methyl)-2-(((2R,6S)-2,6-dimethylmorpholinyl)methyl ester)-6-fluorohexahydro-3H-pyrrolizin-3-one

[0221] ((2R,6R,7aS)-7a-((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-3-oxohexahydro-1H-pyrrolizin-2-yl)methyl-4-methylbenzenesulfonate (5.1 g, 8.6 mmol) (the compound shown in Formula 3) and (2R,6S)-2,6-dimethylmorpholine (8 ml) (the compound shown in Formula 4) were added to a flask and stirred at 100°C for 2 hours. The reaction solution was concentrated and purified by column chromatography (ethyl acetate:dichloromethane = 0-50%) to obtain compound 3-4 (a colorless oil, 4.5 g, 98% yield). LC-MS: m / z: (M+H)+ = 539.4.

[0222] Step 4: Synthesis of ((2R,6R,7aS)-2-((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methanol

[0223] (2R,6R,7aS)-7a-((tert-butyldiphenylsilyl)oxy)methyl)-2-(((2R,6S)-2,6-dimethylmorpholinyl)methyl ester)-6-fluorohexahydro-3H-pyrrolizin-3-one (8 g, 14.85 mmol) (the compound represented by Formula 5) was dissolved in 80 ml of tetrahydrofuran. Lithium aluminum tetrahydride (23 mL, 23 mmol, 1 mol / L) was added under ice-cooling and stirred at 65°C for 2 h. The reaction solution was quenched with 2 ml of saturated ammonium chloride and filtered. The filtrate was concentrated and purified by column chromatography (3 M ammonia methanol: dichloromethane = 0-20%) to obtain compound 3-5 (white solid, 3 g, 70% yield). LC-MS: m / z: (M+H)+=287.2.1H NMR(400MHz, CDCl3)δ5.24(dt,J=53.7,3.3Hz,1H),3.71–3.61(m,2H),3.40(dd,J =10.8,4.1Hz,1H),3.35–3.14(m,3H),3.03(dd,J=14.1,2.8Hz,0.5H),2.92(dd,J= 14.1,2.8Hz,0.5H),2.78–2.63(m,3H),2.48(ddd,J=17.7,11.5,6.4Hz,1H),2.38–2.27(m,2H ),2.17–2.03(m,1.5H),2.01–1.91(m,1.5H),1.75–1.60(m,3H),1.15(dt,J=5.5,2.7Hz,6H).

[0224] Step 5: Synthesis of tert-butyl (1R,5S)-3-(7-chloro-2-(((2R,6R,7aS)-2-((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0225] Tert-butyl (1R,5S)-3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (860 mg, 2 mmol) (the compound shown in Formula 7) and ((2R,6R,7aS)-2-((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methanol (670 mg, 2.3 mmol) (the compound shown in Formula 6) were added to 15 ml of anhydrous acetonitrile, followed by N,N-diisopropylethylamine (800 mg, 6.2 mmol) and stirred at 95°C for 48 h. The reaction solution was concentrated and purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain compound 3-7 (pale yellow solid, 800 mg, 58% yield). LC-MS:m / z:(M+H) + =678.4.

[0226] Step 6: Synthesis of tert-butyl (1R,5S)-3-(2-(((2R,6R,7aS)-2-(((2L,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0227] Tert-butyl (1R,5S)-3-(7-chloro-2-(((2R,6R,7aS)-2-((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (205 mg, 0.3 mmol) (the compound shown in Formula 8) was added. ), 2-(8-ethyl-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (180 mg, 0.526 mmol) (a compound as shown in Formula 9), tetrakistriphenylphosphine palladium (70 mg, 0.06 mmol), cesium carbonate (220 mg, 0.67 mmol) and 0.5 ml of water were added to 8 ml of 1,4-dioxane and stirred at 100 degrees under argon protection overnight. The reaction solution was filtered and concentrated and then purified by column chromatography (methanol: dichloromethane = 0-20%) to obtain compound 3-9 (light yellow solid, 75 mg, yield 29%). LC-MS: m / z: (M+H) + =858.5.

[0228] Step 7: Synthesis of 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,6R,7aS)-2-(((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0229] Tert-butyl (1R,5S)-3-(2-(((2R,6R,7aS)-2-(((2L,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (75 mg, 0.09 mmol) (the compound represented by Formula 10) was dissolved in 2 ml of methanol, and then 2 ml of dioxane hydrochloride (4 mol / L) was added. The mixture was stirred at room temperature for 20 minutes. The reaction mixture was concentrated, and saturated sodium bicarbonate solution was added. The mixture was extracted with a mixture of methanol and dichloromethane (V methanol:V dichloromethane = 10:1). The organic layer was dried over anhydrous sodium sulfate and isolated by thin-layer chromatography (V 7M ammonia methanol:V dichloromethane = 10:1) to obtain compound 3 (50 mg white solid, 80% yield). LC-MS: m / z: (M+H) +=714.4.1H NMR(400MHz, CDCl3)δ8.93(d,J=8.8Hz,1H),7.48(d,J=7.1Hz,1H),7.34–7.24(m,1H),7.13 (t,J=8.9Hz,2H),6.98(d,J=30.0Hz,1H),5.28(d,J=53.6Hz,1H),4.43(t,J=12.1Hz,2H),4 .22(q,J=10.5Hz,2H),3.71–3.39(m,7H),3.15(dt,J=25.9,16.5Hz,2H),2.83–2.52(m,4H) ,2.43–2.07(m,7H),1.82–1.56(m,7H),1.13(t,J=5.7Hz,6H),0.92(td,J=7.3,3.4Hz,3H).

[0230] Example 4

[0231] The synthetic route of compound 4 is as follows:

[0232] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-((2R,6R,7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol (SPH10021):

[0233] The synthetic route is as follows:

[0234] Step 1: Synthesis of tert-butyl (1R,5S)-3-(7-chloro-8-fluoro-2-(((2R,6R,7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0235] Intermediate 4-1 was synthesized by referring to the method for compound 3-5 in Example 3. To a solution of tert-butyl (1R,5S)-3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (200 mg, 0.468 mmol, 1.0 equiv) and ((2R,6R,7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol (120 mg, 0.468 mmol, 1.0 equiv) in dioxane (2 ml) was added N,N-diisopropylethylamine (151 mg, 1.17 mmol, 2.5 equiv). The mixture was heated to 95°C in a sealed tube and stirred for 48 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction, the solvent was removed by rotary evaporation under reduced pressure. The crude product was purified by silica gel column chromatography using a mobile phase of 0% → 10% methanol / dichloromethane over 20 minutes; detector UV: 254 / 220 nm to yield compound 4-2 (light yellow solid, 102 mg, 34% yield). MS (ESI, m / z): 650.3 [M+H]+.

[0236] Step 2: Synthesis of tert-butyl (1R, 5S)-3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(((2R, 6R, 7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0237] Under nitrogen protection and stirring at 25 degrees Celsius, tert-butyl (1R, 5S)-3-(7-chloro-8-fluoro-2-(((2R, 6R, 7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (102 mg, 0.154 mmol, 1.0 equivalent), (( 2-Fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxyborane-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (120 mg, 0.230 mmol, 1.5 eq), Ad2nBuP-Pd-G3 (17 mg, 0.023 mmol, 0.15 eq), potassium phosphate (100 mg, 0.46 mmol, 3.0 eq), tetrahydrofuran solution (4 ml), and water (1 ml). The mixture was heated to 60°C under argon and stirred for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature. The filtrate was filtered through celite and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a 0% → 10% methanol / dichloromethane mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to afford compound 4-4 (white solid, 132 mg, 86%). MS (ESI, m / z): 1000.7 [M+H]+.

[0238] Step 3: tert-Butyl (1R, 5S)-3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-

[0239] Synthesis of ((2R,6R,7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0240] To the reaction flask, tert-butyl (1R, 5S)-3-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(((2R, 6R, 7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (132 mg, 0.132 mmol, 1.0 equiv), cesium fluoride (201 mg, 1.32 mmol, 10 equiv) and N,N-dimethylformamide (5 ml) were added sequentially under nitrogen protection and stirring at 25°C. The mixture was stirred at room temperature under argon for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was added to water, whereupon a white solid precipitated. This solid was filtered and dried to afford compound 4-5 (white solid, 102 mg, 92%). MS (ESI, m / z): 844.6 [M+H]+.

[0241] Step 4: Synthesis of 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-((2R,6R,7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0242] To the reaction flask, tert-butyl (1R,5S)-3-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((2R,6R,7aS)-2-fluoro-6-(morpholinomethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (102 mg, 0.12 mmol, 1.0 equiv), 4N hydrochloric acid in dioxane (0.6 mL), and acetonitrile (1 mL) were added sequentially under nitrogen protection and stirring at 25°C. The mixture was stirred at room temperature under argon protection for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product was purified by HPLC to give the formate salt of compound 4 (yellow solid, 23 mg, 27%). MS (ESI, m / z): 700.3 [M+H] + .

[0243] 1H NMR (400MHz, Methanol-d4) δ9.06 (s, 1H), 7.87 (dd, J = 9.2, 5.7Hz, 1H), 7.42–7.30 (m ,2H),7.21(d,J=2.6Hz,1H),5.48–5.33(m,1H),4.50–4.39(m,2H),4.02(s,2H),3.92 –3.81(m,2H),3.68(t,J=4.7Hz,5H),3.59(s,1H),3.53–3.42(m,2H),2.96–2.86(m,1 H),2.83–2.69(m,1H),2.58–2.38(m,9H),2.08–1.96(m,5H),1.85(t,J=12.4Hz,1H).

[0244] Example 5

[0245] The synthetic route of compound 5 is as follows:

[0246] Step 1: Synthesis of tert-butyl (1R,5S)-3-(2-(((2R,6R,7aS)-2-(((2L,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxy-methoxymethyl)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0247] Tert-butyl (1R, 5S)-3-(7-chloro-2-(((2R, 6R, 7aS)-2-((2R, 6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (340 mg, 0.5 mmol) (compound shown in Formula 1), ((2-fluoro- 6-(Methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxyborane-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane (390 mg, 0.76 mmol) (the compound represented by Formula 2), tetrakistriphenylphosphine palladium (290 mg, 0.25 mmol), cesium carbonate (500 mg, 1.54 mmol), and 1 ml of water were added to 10 ml of 1,4-dioxane and stirred at 100 degrees Celsius overnight under argon. The reaction solution was filtered, concentrated, and purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain compound 5-3 (yellow solid, 270 mg, 52% yield). LC-MS: m / z: (M+H) + =1028.6.

[0248] Step 2: Synthesis of tert-butyl (1R,5S)-3-(2-(((2R,6R,7aS)-2-(((2L,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0249] Tert-butyl (1R, 5S)-3-(2-(((2R, 6R, 7aS)-2-(((2L, 6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoro-7-(7-fluoro-3-(methoxy-methoxymethyl)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (350 mg, 0.34 mmol) (the compound shown in Formula 3) and cesium fluoride (700 mg, 4.63 mmol) were added to 10 ml of N,N-dimethylformamide and stirred at room temperature for 1 hour. The reaction solution was filtered, concentrated, and then purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain compound 5-4 (yellow solid, 260 mg, yield 87%). LC-MS: m / z: (M+H) + =872.4.

[0250] Step 3: Synthesis of 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,6R,7aS)-2-(((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0251] Tert-butyl (1R,5S)-3-(2-(((2R,6R,7aS)-2-(((2L,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (280 mg, 0.32 mmol) (the compound shown in Formula 4) was dissolved in 2 ml of acetonitrile, and then 2 ml of dioxane hydrochloride (4 mol / L) was added. The mixture was stirred at room temperature for 20 minutes. The reaction mixture was concentrated, and saturated sodium bicarbonate solution was added. The mixture was extracted with a mixture of methanol and dichloromethane (V methanol:V dichloromethane = 10:1). The organic layer was dried over anhydrous sodium sulfate and isolated by thin-layer chromatography (V 7M ammonia methanol:V dichloromethane = 1:7) to obtain compound 5 (white solid, 60 mg, yield 24%). LC-MS: m / z: (M+H) + =728.4.

[0252] 1H NMR(400MHz, CDCl3)δ8.89(d,J=12.1Hz,1H),7.57(dd,J=8.6,5.8Hz,1H),7.27–7.02( m,3H),5.28(d,J=53.4Hz,1H),4.55(d,J=11.5Hz,1H),4.40(d,J=11.0Hz,1H),4.31–4 .14(m,2H),3.58(dd,J=41.5,8.8Hz,7H),3.42(s,1H),3.27–3.06(m,2H),2.81–2.54( m,5H),2.26(ddd,J=50.3,32.2,8.8Hz,5H),1.81–1.56(m,7H),1.12(t,J=6.0Hz,6H).

[0253] Example 6

[0254] The synthetic route of compound 6 is as follows:

[0255] Step 1: Synthesis of tert-butyl (1R,5S)-3-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2-(((2R,6R,7aS)-2-(((1R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0256] Tert-butyl (1R,5S)-3-(7-chloro-2-(((2R,6R,7aS)-2-((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (205 mg, 0.3 mmol) (compound shown in Formula 1), N,N- Bis(4-methoxybenzyl)-4-methyl-5-(trifluoromethyl)-6-(trimethyltinyl)pyridin-2-amine (280 mg, 0.48 mmol) (the compound represented by Formula 2), lithium chloride (100 mg, 2.38 mmol), cuprous iodide (60 mg, 0.31 mmol), and tetrakistriphenylphosphine palladium (180 mg, 0.15 mmol) were added to 8 ml of N,N-dimethylformamide and stirred at 120°C overnight under argon. The reaction mixture was filtered and concentrated to obtain the crude product, which was separated and purified by thin-layer chromatography (methanol:dichloromethane = 1:10) to obtain compound 6-3 (140 mg white solid, 43% yield). LC-MS: m / z: (M+H) + =1058.6.

[0257] Step 2: Synthesis of 6-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,6R,7aS)-2-(((2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-4-methyl-5-(trifluoromethyl)pyridin-2-amine

[0258] Tert-butyl (1R,5S)-3-(7-(6-(bis(4-methoxybenzyl)amino)-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-2-(((2R,6R,7aS)-2-(((1R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (140 mg, 0.13 mmol) (the compound shown in Formula 3) was dissolved in 5 ml of trifluoroacetic acid and stirred at 60 degrees for 4 hours. The reaction mixture was concentrated and added with a saturated sodium carbonate solution. The mixture was extracted with a mixture of methanol and dichloromethane (V methanol:V dichloromethane = 10:1). The organic layer was dried over anhydrous sodium sulfate and isolated using thin-layer chromatography (V 7M ammonia methanol:V dichloromethane = 1:8) to obtain compound 6 (white solid, 60 mg, yield 63%). LC-MS: m / z: (M+H) + =718.4.1H NMR (400MHz, CDCl3) δ9.01 (s, 1H), 6.50 (s, 1H), 5.31 (d, J = 52.6Hz, 1H), 4.82 (s, 2H), 4.57 (d, J=11.8Hz,2H),4.32(d,J=10.3Hz,1H),4.18(d,J=10.3Hz,1H),3.76–3.61(m,6H),3.46(t,J=6 .6Hz,1H),3.20(dt,J=41.0,14.0Hz,2H),2.84–2.68(m,3H),2.63(dd,J=11.6,5.8Hz,1H),2. 50(d,J=1.4Hz,3H),2.44–2.29(m,4H),2.16(m,1H),1.88–1.63(m,7H),1.16(t,J=6.1Hz,6H).

[0259] Preparation Example 2: The synthetic route of intermediate 29-5 is as follows:

[0260] Step 1:

[0261] To a reaction flask, (2R,7aS)-2-fluorotetrahydro-1H-pyrrolizine-7a(5H)-methanol (30 g, 179.0 mmol, 1.0 equiv), imidazole (15.4 g, 214.8 mmol, 1.2 equiv), and 300 mL of dichloromethane were added sequentially under nitrogen at 0°C. Tert-butyldiphenylsilyl chloride (67.3 g, 232.6 mmol, 1.3 equiv) was then slowly added. The resulting mixture was stirred at 25°C under nitrogen for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was quenched with saturated sodium bicarbonate solution and extracted with dichloromethane (300 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a 0%→10% methanol / dichloromethane mobile phase gradient elution. The resulting fractions were evaporated to remove the solvent to give compound 29-1 (colorless oil, 63 g, 84% yield). MS(ESI,m / z):398.2[M+H]+; 1H NMR (300MHz, CDCl3) δ7.77–7.64(m,4H),7.50–7.35(m,6H),5.35–5.09(m,1H),3.49(d,J=9.6Hz,1H),3.38(d,J=9.6 Hz,1H),3.27–2.99(m,3H),2.98–2.83(m,1H),2.26–2.14(m,1H),2.13–1.94(m,2H),1.95–1.63(m,3H),1.09(s,9H).

[0262] Step 2:

[0263] Under stirring conditions at 0 degrees Celsius, a solution of compound 29-1 (39 g, 93.2 mmol, 1.0 equivalent) in carbon tetrachloride (400 ml) was added with a solution of ruthenium trichloride hydrate (4.42 g, 18.6 mmol, 0.2 equivalent) in water (400 ml) and sodium periodate (104.9 g, 465.9 mmol, 5.0 equivalent). The mixture was stirred at 25 degrees Celsius for 1 hour, and the reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, the reaction solution was cooled to room temperature and quenched with water (500 ml). The resulting mixture was extracted with dichloromethane (500 ml × 3), the organic phases were combined, and then dried over anhydrous sodium sulfate. The desiccant was filtered to remove the desiccant, and the filtrate was evaporated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 60% petroleum ether / methyl tert-butyl ether as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to afford compound 29-2 (white solid, 19 g, 47% yield). MS (ESI, m / z): 412.2 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ7.66–7.59(m,4H),7.48–7.37(m,6H),5.38–5.15(m,1H),4.21–4.08(m,1H),3.63–3.53(m,1H),3.49–3.39(m, 1H),3.17–3.00(m,1H),2.79–2.66(m,1H),2.44–2.34(m,1H),2.33–2.21(m,1H),2.21–2.10(m,1H),2.05–1.92(m,2H),1.04(s,9H).

[0264] Step 3:

[0265] To a solution of compound 29-2 (16 g, 36.930 mmol, 1.0 eq) in anhydrous tetrahydrofuran (150 ml) and hexamethylphosphoric triamide (25 ml) was added dropwise a solution of lithium diisopropylamide in tetrahydrofuran (46.5 ml, 1 mol / L, 1.5 eq) under nitrogen protection and stirring at -78 degrees Celsius. The resulting mixture was reacted for 30 minutes under nitrogen protection and stirring at -78 degrees Celsius. Paraformaldehyde (3.5 g, 73.860 mmol, 2.0 eq) was added to the reaction system under nitrogen protection and stirring at -78 degrees Celsius, and the mixture was then slowly heated to 25 degrees Celsius. The mixture was reacted for 2.5 hours under nitrogen protection and stirring at 25 degrees Celsius. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction, saturated aqueous ammonium chloride (500 mL) was slowly added to the reaction mixture at 0°C to quench the reaction. The mixture was extracted with ethyl acetate (500 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The desiccant was filtered to remove the desiccant, and the filtrate was evaporated to remove the solvent under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography using a mobile phase gradient of 0% → 100% petroleum ether / methyl tert-butyl ether. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 29-3 (yellow oil, 5.5 g, 32% yield). MS (ESI, m / z): 442.2 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ7.64–7.61(m,4H),7.47–7.38(m,6H),5.33–5.18(m,1H),4.21–4.12(m,1H),3.82–3.78(m,1H),3.68–3.62(m,1H), 3.59(d,J=10.4Hz,1H),3.44(d,J=10.4Hz,1H),3.14–2.97(m,2H),2.33–2.16(m,2H),2.06–1.94(m,1H),1.84–1.80(m,1H),1.05(s,9H).

[0266] Step 4:

[0267] To a 250 mL three-necked flask, compound 29-3 (2.8 g, 6.02 mmol, 1.0 eq), allyl bromide (0.92 g, 7.22 mmol, 1.2 eq), and N,N-dimethylformamide (39 mL) were added sequentially under nitrogen protection and stirring at 25°C. The reaction system was then cooled to zero degrees Celsius. Sodium hydride (60%, 0.28 g, 7.22 mmol, 1.2 eq) was added portionwise to the reaction system under nitrogen protection and stirring at zero degrees Celsius. The resulting mixture was slowly heated to 25°C and then reacted under nitrogen protection and stirring at 25°C for 2 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, the reaction solution was cooled to zero degrees Celsius and quenched by adding saturated aqueous ammonium chloride solution (500 mL) to the reaction solution under stirring at zero degrees Celsius. The mixture was extracted with ethyl acetate (500 ml x 3), and the combined organic phases were dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the filtrate was evaporated to remove the solvent under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography using a mobile phase gradient of 0% → 40% petroleum ether / methyl tert-butyl ether. The resulting fractions were evaporated to remove the solvent under reduced pressure to obtain compound 29-4 (yellow oil, 1.57 g, 51% yield). MS (ESI, m / z): 482.2 [M+H] + ; 1 H NMR (300MHz, CDCl3) δ7.73–7.57(m,4H),7.55–7.35(m,6H),6.02–5.74(m,1H),5.47 –5.08(m,3H),4.24–4.09(m,1H),4.06–3.95(m,2H),3.86–3.75(m,1H),3.64–3. 40(m,3H),3.25–3.00(m,2H),2.43–2.20(m,2H),2.12–1.90(m,2H),1.07(s,9H).

[0268] Step 5:

[0269] To a solution of compound 29-4 (1.5 g, 3.1 mmol, 1.0 eq) in N,N-dimethylformamide (15 ml) was added lithium aluminum tetrahydride (0.18 g, 4.67 mmol, 1.5 eq) in portions under nitrogen protection and stirring at 0°C. The resulting mixture was reacted at 60°C under nitrogen protection and stirring for 2 hours. The reaction process was monitored by thin-layer chromatography. After completion of the reaction, ice water (0.2 ml) was added to the reaction solution to quench the reaction, followed by the addition of 0.2 ml of a 20% NaOH solution and finally 0.6 ml of water. After stirring for 15 minutes, the insoluble matter was removed by filtration, and the filter cake was washed with a tetrahydrofuran / methanol (10 / 1) mixture (10 ml x 3). The combined filtrates were evaporated to remove the solvent under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% dichloromethane / methanolic ammonia as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to afford compound 29-5 (colorless oil, 0.53 g, 75% yield). MS (ESI, m / z): 230.2 [M+H] + .

[0270] Step 6:

[0271] To a reaction flask, triethylenediamine (39 mg, 0.33 mmol, 0.2 equiv), compound 297-2 (1230 mg, 1.80 mmol, 1.1 equiv), cesium carbonate (1130 mg, 3.3 mmol, 2.0 equiv), compound 29-5 (400 mg, 1.816 mmol, 1.0 equiv), and N,N-dimethylformamide (5 ml) were added sequentially under nitrogen at 25°C. The resulting mixture was stirred at 80°C under nitrogen for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the crude product was purified by reverse-phase chromatography (C18 column) using a 5%→95% methanol / water mobile phase (0.1% ammonium bicarbonate in water) over 25 minutes; the detector was UV 254 / 220 nm. Compound 29-6 was obtained as an off-white solid, 760 mg, 51% yield. MS (ESI, m / z): 836.3 [M+H] + .

[0272] Step 7:

[0273] Compound 29-6 (460 mg) obtained in step 6 of this example was subjected to chiral separation by high-performance liquid chromatography: chiral column CHIRAL ART Cellulose-SC, 2×25 cm, 5 μm; mobile phase A: n-hexane (0.5%, 2 mol / L ammonia in methanol), mobile phase B: ethanol; flow rate: 20 ml / min; elution with 20% phase B over 12 minutes, detector UV 205 / 226 nm, to obtain two products. The product with the shorter retention time (6.0 minutes) was compound 29-6a (off-white solid, 170 mg, 37% recovery), MS (ESI, m / z): 836.4 [M+H] + The product with a longer retention time (8.7 minutes) was compound 29-6b (off-white solid, 178 mg, recovery rate 39%), MS (ESI, m / z): 836.4 [M+H] + .

[0274] Step 8:

[0275] Compound 29-6a (90 mg, 0.102 mmol, 1.0 equiv), 1,3-dimethylbarbituric acid (33.62 mg, 0.204 mmol, 2 equiv), tetrakis(triphenylphosphine)palladium (12.44 mg, 0.01 mmol, 0.05 equiv), and dichloromethane (0.5 ml) were added sequentially to a reaction flask at 25°C under nitrogen and stirred. The resulting mixture was reacted at 25°C for 48 hours, with the reaction progress monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the excess solvent was removed by concentration under reduced pressure to yield the crude product. The crude product was purified by silica gel column chromatography using a 0% to 8% ammonia methanol / dichloromethane mobile phase gradient. The resulting fraction was then evaporated to remove the solvent under reduced pressure to yield compound 29-7 (yellow solid, 83 mg, 99% yield). MS (ESI, m / z): 796.3 [M+H] + .

[0276] Step 9:

[0277] To a solution of compound 29-7 (20 mg, 0.025 mmol, 1 eq) in ethyl acetate (10 mL) was added 2-iodoacylbenzoic acid (20 mg, 0.075 mmol, 3 eq) under stirring at 25°C. The mixture was reacted at 80°C for 5 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, the reaction mixture was cooled to room temperature and filtered and concentrated to obtain the crude product 29-8 (white solid, 16 mg, 80% yield). The crude product was used directly in the next step. MS (ESI, m / z): 794.4 [M+H] + .

[0278] Example 7

[0279] The synthetic route of compound 7 is as follows:

[0280] The synthetic route of 4-((S or R)-4-((1R,5S)-3,8-diazabicyclo[3.2.1]octyl-3-yl)-2-(((2R,6R,7aS)-2-(((2S,6R)-2,6-dimethylmorpholino)methyl)-6-fluorohexahydro-1H-pyrrolidine-7a(5H)-yl)methoxy)-6,8-difluoroquinazolin-7-yl)-5-ethyl-6-fluoronaphthalene-2-ol trihydrochloride 7 is as follows:

[0281] Step 1:

[0282] To a solution of compound 29-8 (25 mg, 0.030 mmol, 1 eq) in methanol (2 mL) were added (2R,6S)-2,6-dimethylmorpholine (21.76 mg, 0.180 mmol, 6 eq), acetic acid (13.24 mg, 0.210 mmol, 7 eq), and sodium cyanoborohydride (13.85 mg, 0.210 mmol, 7 eq) in sequence at 0°C with stirring. The resulting mixture was stirred at room temperature for 16 hours. The reaction was monitored by liquid chromatography-mass spectrometry. After completion of the reaction, the reaction solution was directly purified by reverse-phase chromatography (C18 column) using a 10%→50% methanol / water mobile phase (10 mmol / L ammonium bicarbonate) over 10 minutes; detection: UV 254 / 220 nm. Compound 7-1 was obtained as a white solid, 13 mg, 46% yield. MS (ESI, m / z): 893.4 [M+H] + .

[0283] Step 2:

[0284] To a solution of compound 7-1 (13 mg, 0.01 mmol, 1 eq) in methanol (2 mL) was added dropwise a solution of hydrogen chloride in 1,4-dioxane (2 mL, 7 mol / L) under stirring at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The reaction was monitored by liquid chromatography-mass spectrometry. After completion of the reaction, the solvent was removed by rotary evaporation under reduced pressure to obtain a crude product. The crude product was purified by reverse phase chromatography (C18 column) using a mobile phase of 10% → 50% acetonitrile / water (0.1% hydrochloric acid) over 25 minutes; detector: UV 254 / 220 nm. Compound 7 hydrochloride was obtained as a yellow solid, 8.1 mg, yield 66%. MS (ESI, m / z): 749.3 [M+H] + ; 1H NMR (400MHz, CD3OD) δ7.93(d,J=9.1Hz,1H),7.71(dd,J=9.1,5.8Hz,1H),7.35(d,J=2.1Hz ,1H),7.28(t,J=9.3Hz,1H),7.03(d,J=2.6Hz,1H),5.74-5.61(m,1H),5.16-4.88(m,5H), 4.39-4.20(m,4H),4.06-3.95(m,5H),3.63-3.40(m,5H),2.99(brs,1H),2.77–2.71(m,4H ),2.55(brs,1H),2.44(brs,1H),2.29-2.16(m,5H),1.25-1.24(m,6H),0.86-0.83(m,3H); 19 F NMR (376MHz, CD3OD) δ-114.03,-120.61,-125.56,-174.33.

[0285] Example 8

[0286] The synthetic routes of compounds 8a and 8b are as follows:

[0287] The specific steps are as follows:

[0288] Step 1:

[0289] Compound 8-1 (pale yellow solid) was obtained by replacing 2-chloro-3-fluoro-4-aminopyridine with 3-chloro-2,4-difluoroaniline and referring to the synthetic method of compound 320-6. MS (ESI, m / z): 489.1 / 491.0 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 7.44–7.36 (m, 1H), 4.48–4.31 (m, 4H), 3.75–3.54 (m, 2H), 2.08–1.92 (m, 2H), 1.79–1.70 (m, 2H), 1.54 (s, 9H).

[0290] Compound 8-1 (150 mg, 0.3 mmol), compound 3-5 (90 mg, 0.31 mmol), triethylenediamine (12 mg, 0.1 mmol), and cesium carbonate (300 mg, 0.92 mmol) were added to 10 ml of anhydrous acetonitrile and stirred at 60°C overnight. The reaction mixture was filtered, concentrated, and purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain 180 mg of a brown solid, compound 8-2, in a 79% yield. LC-MS: m / z: (M+H) + =739.3.

[0291] Step 2:

[0292] Synthesis of tert-butyl (1R,5S)-3-(7-(3-chloro-2-cyclopropyl-5-(methoxy-methoxy)phenyl)-2-(((2R,6R,7aS)-2-(((2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0293] Compound 8-2 (180 mg, 0.24 mmol), compound 8-3 (150 mg, 0.44 mmol), water (1 ml), cesium carbonate (200 mg, 0.61 mmol), and tetrakistriphenylphosphine palladium (115 mg, 0.1 mmol) were added to 7 ml of 1,4-dioxane and stirred at 105°C overnight under argon. The reaction mixture was filtered, concentrated, and purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain 190 mg of a brown solid, compound 8-4, in an 89% yield. LC-MS: m / z: (M+H) + =871.4.

[0294] Step 3:

[0295] Synthesis of 3-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,6R,7aS)-2-([(2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-6,8-difluoroquinazolin-7-yl)-5-chloro-4-cyclopropylphenol

[0296] Compound 8-4 (185 mg, 0.21 mmol) (the compound represented by Formula 5) was added to 2 mL of dichloromethane, followed by the addition of 2 mL of trifluoroacetic acid, and stirred at room temperature for 0.5 hours. The reaction mixture was filtered, concentrated, and purified by thin-layer chromatography on silica gel (3 M ammonia methanol: dichloromethane = 1:10) to yield 120 mg of a white solid in a 77% yield. Chiral separation was then performed (column: CHIDAIPAKR IC column, 250 × 4.6 mm, 5 μm, mobile phase: A: 0.1% diethylamine-n-hexane, B: 0.1% diethylamine-ethanol, flow rate: 0.8 mL / min, column temperature: 35°C, detection wavelength: UV 254) to yield 24 mg of compound 8a (retention time 8.933 min) and 22 mg of compound 8b (retention time 10.147 min), both white solids.

[0297] Compound 8a:

[0298] LC-MS:m / z:(M+H) + =727.4. 1 H NMR (400MHz, CDCl3) δ7.30 (s, 1H), 6.95 (d, J = 2.4Hz, 1H), 6.81 (d, J = 2.1Hz, 1H), 5.29 (d, J = 54.8Hz, 1 H),4.40(d,J=12.5Hz,2H),4.20(m,2H),3.73–3.61(m,4H),3.57(m,2H),3.43(s,1H),3.12(m,2H),2. 82–2.52(m,4H),2.44–2.19(m,5H),1.77–1.66(m,5H),1.32–1.24(m,5H),1.14(dt,J=14.7,7.4Hz,6H ),0.79–0.68(m,1H),0.42(d,J=4.5Hz,1H),0.31(dd,J=9.6,4.9Hz,1H),0.08(dd,J=9.1,4.3Hz,1H).

[0299] Compound 8b:

[0300] LC-MS:m / z:(M+H) + =727.4. 1 H NMR (400MHz, CDCl3) δ7.31(s,1H),6.96(d,J=2.4Hz,1H),6.71(d,J=1.9Hz,1H),5.30(d,J=54.7Hz ,1H),4.37(t,J=12.5Hz,2H),4.20(s,2H),3.72–3.42(m,7H),3.20(dd,J=32.4,18.3Hz,2H),2.84 –2.54(m,4H),2.45–2.10(m,5H),1.78–1.66(m,3H),1.28(s,5H),1.14(dd,J=6.2,2.7Hz,6H),0.6 9(d,J=4.8Hz,1H),0.47(d,J=4.7Hz,1H),0.26(dd,J=9.6,4.9Hz,1H),0.11(dd,J=9.5,4.7Hz,1H).

[0301] Example 9

[0302] The synthetic route of compound 9 is as follows:

[0303] Step 1: tert-Butyl (3-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonane-9-carboxylate

[0304] Compound 320-5 (800 mg, 3.17 mmol), compound 9-1 (717 mg, 3.17 mmol), and DIEA (1.23 g, 9.50 mmol) were dissolved in dichloromethane (10 mL) under nitrogen at 25°C. The mixture was stirred at 20°C for 1 hour. The reaction solution was concentrated, and the crude product was purified by column chromatography (ethyl acetate / petroleum ether = 0-25%) to obtain compound 9-2 (white solid, 1.1 g, 78% yield). MS (ESI, m / z): 442.0 [M+H]+.

[0305] Step 2: Synthesis of tert-butyl 3-(7-chloro-2-(((2R,6R,7aS)-2-((2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0306] Compound 9-2 (310 mg, 0.7 mmol), compound 3-5 (200 mg, 0.7 mmol), and N,N-diisopropylethylamine (0.3 ml, 1.7 mmol) were added to 10 ml of anhydrous acetonitrile and stirred at 60°C overnight. The reaction mixture was filtered, concentrated, and purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain 260 mg of a brown solid, compound 9-3, in a 53% yield. LC-MS: m / z: (M+H) + =692.4.

[0307] Step 3: Synthesis of tert-butyl 3-(2-(((2R,6R,7aS)-2-(((2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(8-ethyl-3-(methoxymethoxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0308] Compound 9-3 (80 mg, 0.11 mmol), compound 2-2 (80 mg, 0.23 mmol) (the compound represented by Formula 4), water (1 ml), cesium carbonate (120 mg, 0.37 mmol), and tetrakistriphenylphosphine palladium (70 mg, 0.06 mmol) were added to 6 ml of 1,4-dioxane and stirred at 105°C overnight under argon. The reaction mixture was filtered, concentrated, and purified by column chromatography (methanol:dichloromethane = 0-15%) to obtain 65 mg of a brown solid, compound 9-4, in a 64% yield. LC-MS: m / z: (M+H) + =872.5.

[0309] Step 4: Synthesis of 4-(4-(3,9-diazabicyclo[4.2.1]nonan-3-yl)-2-(((2R,6R,7aS)-2-([(2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethylnaphthol-2-ol

[0310] Compound 9-4 (60 mg, 0.07 mmol) was added to 2 ml of acetonitrile, followed by 2 ml of 4 M hydrochloric acid in dioxane, and stirred at room temperature for 0.5 hours. The reaction mixture was filtered, concentrated, and purified by thin-layer chromatography on silica gel (7 M ammonia methanol: dichloromethane = 1:7) to afford 45 mg of compound 9 as a white solid, in an 89% yield. LC-MS: m / z: (M+H) + =728.5.1H NMR(400MHz, CDCl3)δ9.00(d,J=13.3Hz,1H),7.50(d,J=7.2Hz,1H),7.34–7.25(m,1H),7.12(t,J =8.9Hz,2H),6.96(d,J=32.9Hz,1H),5.29(d,J=54.9Hz,1H),4.52(s,1H),4.36–4.02(m,3H),3.98 –3.39(m,8H),3.32–3.03(m,2H),2.83–2.53(m,4H),2.43–2.21(m,6H),2.14(d,J=10.0Hz,1H),2 .05–1.80(m,3H),1.68(ddd,J=51.8,31.2,13.7Hz,5H),1.13(t,J=5.3Hz,6H),0.97–0.86(m,3H).

[0311] Example 10

[0312] The synthetic route of compound 10 is as follows:

[0313] Step 1: tert-Butyl 3-(2-(((2R,6R,7aS)-2-(((1R,5S)-8-oxo-3-azabicyclo[3.2.1]oct-3-yl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-chloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0314] Compound 9-2 (340 mg, 0.77 mmol), compound 1-5 (218 mg, 0.77 mmol), and DIEA (248 mg, 1.92 mmol) were dissolved in acetonitrile (5 mL) under nitrogen and stirred at 25°C. The mixture was stirred at 100°C for 72 hours. The reaction mixture was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-12%) to obtain compound 10-1 (colorless oil, 390 mg, 73.51% yield). MS (ESI, m / z): 690.0 [M+H] + .

[0315] Step 2:

[0316] Compound 10-1 (240 mg, 0.35 mmol), compound 2-2 (82 mg, 0.24 mmol), potassium phosphate (138 mg, 0.65 mmol), and Ad2nBuP-Pd-G3 (16 mg, 0.022 mmol) were dissolved in tetrahydrofuran (2 mL) under nitrogen at 25°C. The reaction mixture was stirred at 60°C under nitrogen for 3 hours. The reaction mixture was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-10%) to obtain compound 10-2 (brown oil, 90 mg, 47.60% yield). MS (ESI, m / z): 870.0 [M+H] + .

[0317] Step 3:

[0318] Compound 10-2 (90 mg, 0.10 mmol) was dissolved in acetonitrile (1 mL) at 0°C, and a 4M solution of dioxane hydrochloride (1 mL) was added. The reaction mixture was stirred at 0°C for 1 hour, concentrated, diluted with water (10 mL), and neutralized to pH 8 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative HPLC to afford the formate salt of compound 10 (white solid, 50 mg, 60.13% yield). MS (ESI, m / z): 726.0 [M+H]+.

[0319] 1 H NMR (400MHz, MeOD) δ9.14(d,J=3.4Hz,1H),8.42(s,1H),7.66(d,J=8.1Hz,1H),7.39(t,J=7.7H z,1H),7.32(d,J=2.6Hz,1H),7.19(d,J=6.8Hz,1H),7.04(d,J=2.5Hz,1H),5.49(d,J=52.2Hz,1 H),4.67–4.46(m,3H),4.26(t,J=24.3Hz,6H),3.98(s,1H),3.77–3.46(m,3H),3.00(t,J=11.0H z,1H),2.86–2.57(m,3H),2.55–1.77(m,20H),1.41–1.27(m,1H),0.91(dt,J=10.1,7.5Hz,3H).

[0320] Example 11

[0321] 4-(2-(2R,6R,7aS)-2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)methyl)-6-fluorotetrahydro-1H-pyrrolidin-7a(5H)-methoxy)-4-(3,9-diazabicyclo[4.2.1]nonan-3-yl)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0322] The synthetic route of compound 11 is as follows:

[0323] Step 1:

[0324] Compound 9-2 (240 mg, 0.35 mmol), compound 1-8 (196 mg, 0.38 mmol), cesium carbonate (201 mg, 1.04 mmol), and tetrakis(triphenylphosphine)palladium (201 mg, 174 mmol) were dissolved in dioxane (1 mL) and water (0.1 mL) under nitrogen protection and stirring at 25°C. The reaction solution was stirred at 90°C under nitrogen protection for 16 hours. The reaction solution was filtered and concentrated, and the crude product was purified by column chromatography (methanol / dichloromethane = 0-10%) to obtain compound 11-1 (yellow solid, 100 mg, yield 27.64%). MS (ESI, m / z): 1040.0 [M+H] + .

[0325] Step 2:

[0326] Compound 11-1 (100 mg, 0.096 mmol) was dissolved in DMF (1 mL) under nitrogen and stirred at 25°C. CsF (146 mg, 0.96 mmol) was added. The reaction mixture was stirred at 25°C for 1 hour, diluted with water (10 mL), and extracted with ethyl acetate (10 mL x 2). The organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative TLC (dichloromethane / methanol = 10:1) to obtain compound 11-2 (yellow solid, 50 mg, 58.84% yield). MS (ESI, m / z): 854.0 [M+H]+.

[0327] Step 3:

[0328] Compound 11-2 (50 mg, 0.056 mmol) was dissolved in acetonitrile (1 mL) at 0°C, and a 4M solution of dioxane hydrochloride (1 mL) was added. The reaction mixture was stirred at 0°C for 1 hour, concentrated, diluted with water (10 mL), and neutralized to pH 8 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by preparative HPLC to afford the formate salt of compound 11 (yellow solid, 15 mg, 44.81% yield). MS (ESI, m / z): 740.0 [M+H]+.

[0329] 1H NMR(400MHz,MeOD)δ9.09(d,J=10.1Hz,1H),8.46(s,1H),7.89(dd,J=8.9,5.8Hz,1H),7.43–7.31(m,2H),7.27–7.20(m,1H),5.52–5.34(m ,1H),4.76–4.62(m,1H),4.50–3.85(m,9H),3.66–3.36(m,4H),2.91(d,J=9.8Hz,1H),2.65(dd,J=27.7,10.8Hz,3H),2.54–1.70(m,18H).

[0330] Example 12

[0331] 4-(4-(3,9-diazabicyclo[4.2.1]nonan-3-yl)-2-((2R,6R,7aS)-2-((2S,6R)-2,6-dimethylmorpholino)methyl)-6-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0332] The synthesis procedure of the formate salt of compound 12 is the same as that of Example 11:

[0333] LC-MS:m / z:(M+H) + =742.4.1H NMR (400MHz, MeOD) δ9.14–9.04(m,1H),8.30(s,3H),7.89(dd,J=8.6,5.3Hz,1H),7.43–7.30(m,2H),7.30–7.21(m,1H),5.54(d,J=51.4H z,1H),4.80–4.17(m,7H),4.10–3.58(m,6.5H),3.38(d,J=10.8Hz,0.5H),3.15–2.86(m,4H),2.79–1.77(m,14H),1.13(t,J=7.2Hz,6H).

[0334] Example 13

[0335] 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2R,6R,7aS)-2-([(2R,6S)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-6,8-difluoroquinazolin-7-yl)-7-fluorobenzo[d]thiazol-2-amine:

[0336] The synthetic route of compound 13 is as follows:

[0337] Step 1:

[0338] Sodium bicarbonate (267 mg, 3.18 mmol, 5 eq) was added to a solution of compound 8-1 (300 mg, 0.635 mmol, 1.0 eq) and compound 13-1 (238 mg, 0.762 mmol, 1.2 eq) in dioxane (8 ml) and water (1 ml). The mixture was purged with argon three times, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (104 mg, 0.127 mmol, 0.2 eq) was added. The mixture was heated to 105°C and stirred for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the solvent was removed by rotary evaporation under reduced pressure. The crude product was purified by silica gel column chromatography, eluting with a mobile phase of 0% → 10% petroleum ether / ethyl acetate over 20 minutes; detector UV 254 / 220 nm; to afford compound 13-2 (pale yellow solid, 398 mg, 95% yield). MS (ESI, m / z): 661.3 [M+H]+.

[0339] Step 2:

[0340] Compound 13-2 (130 mg, 0.196 mmol, 1.0 equiv), compound 3-5 (75.8 mg, 0.265 mmol, 1.3 equiv), sodium hydroxide (16.3 mg, 0.408 mmol, 2.3 equiv), and tetrahydrofuran solution (4 ml) were added sequentially to a reaction flask under nitrogen and stirred at 25°C. The mixture was heated to 60°C under argon and stirred for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature. The filtrate was filtered through celite and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography using a 0% → 10% methanol / dichloromethane mobile phase. The resulting fraction was evaporated to remove the solvent and afforded compound 13-3 (white solid, 151 mg, 78%). MS (ESI, m / z): 927.1 [M+H]+.

[0341] Step 3:

[0342] Compound 13-3 (115 mg, 0.12 mmol, 1.0 eq), 4N hydrochloric acid in dioxane (1.2 mL), and acetonitrile (1 mL) were added sequentially to the reaction flask under nitrogen and stirring at 25°C. The mixture was stirred at room temperature under argon for 6 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction, the reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was purified by HPLC to obtain the formate salt of compound 13 (yellow solid, 68 mg, 78%). MS (ESI, m / z): 727.3 [M+H]+.

[0343] 1 H NMR (400MHz, DMSO-d6) δ8.00(d,J=48.3Hz,2H),7.65(d,J=10.4Hz,1H),7.17(d,J=96.9Hz,4H ),6.66(s,2H),5.42–5.18(m,1H),4.54–4.28(m,2H),4.21–3.99(m,2H),3.72(dd,J=28.2,13. 7Hz,2H),3.63(s,5H),3.20–2.87(m,2H),2.73(dd,J=25.8,11.2Hz,1H),2.11(d,J=136.3Hz, 6H), 1.75 (s, 6H), 1.53 (dt, J = 33.7, 9.6Hz, 2H), 1.28 (d, J = 40.0Hz, 4H), 0.98 (d, J = 6.1Hz, 2H).

[0344] Example 14

[0345] Compound 14a and Compound 14b:

[0346] The synthetic routes of compounds 14a and 14b are as follows:

[0347] Step 1:

[0348] Potassium phosphate (649 mg, 3.06 mmol, 3 equiv) was added to a solution of compound 8-1 (472 mg, 1.02 mmol, 1.0 equiv) and compound 14-1 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (506 mg, 1.29 mmol, 1.3 equiv) in dioxane (20 ml) and water (5 ml). The mixture was purged with argon three times, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (166 mg, 0.204 mmol, 0.2 equiv) was added. The mixture was heated to 105°C and stirred for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the solvent was removed by rotary evaporation under reduced pressure. The crude product was purified by silica gel column chromatography, eluting with a mobile phase of 0% → 10% petroleum ether / ethyl acetate over 20 minutes; detector UV 254 / 220 nm; to afford compound 14-2 (light yellow solid, 502 mg, 67% yield). MS (ESI, m / z): 741.3 [M+H] + .

[0349] Step 2:

[0350] Compound 14-2 (502 mg, 0.675 mmol, 1.0 eq), N,N-dimethylformamide (20 ml), p-toluenesulfonic acid (6 mg, 0.034 mmol, 0.05 eq), sodium hydride (16.3 mg, 0.408 mmol, 2.3 eq), and N-iodosuccinimide (759 mg, 3.37 mmol, 5.0 eq) were added sequentially to the reaction flask under nitrogen protection and stirring at 25°C. The mixture was stirred at room temperature under argon protection for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction, water (5 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was purified by silica gel column chromatography using a mobile phase of 0% → 20% ethyl acetate / petroleum ether. The resulting fraction was evaporated to remove the solvent under reduced pressure to yield compound 14-3 (white solid, 362 mg, 62%). MS (ESI, m / z): 867.1 [M+H]+.

[0351] Step 3:

[0352] Compound 14-3 (240 mg, 0.277 mmol, 1.0 equiv), N,N-dimethylacetamide (8 mL), cuprous iodide (1.05 g, 5.44 mmol, 20 equiv), and methyl fluorosulfonyldifluoroacetate (1.6 g, 8.31 mmol, 30 equiv) were added sequentially to a reaction flask under nitrogen and stirred at 25°C. The mixture was heated to 105°C under argon and stirred for 16 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, water (5 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using a mobile phase of 0% → 20% ethyl acetate / petroleum ether. The resulting fraction was evaporated to remove the solvent and afforded compound 14-4 (white solid, 212 mg, 95%). MS (ESI, m / z): 809.1 [M+H] + .

[0353] Step 4:

[0354] Compound 14-4 (130 mg, 0.16 mmol, 1.0 eq), compound 3-5 (61.9 mg, 0.217 mmol, 1.3 eq), sodium hydroxide (13.3 mg, 0.332 mmol, 2.3 eq), and tetrahydrofuran solution (4 ml) were added sequentially to a reaction flask under nitrogen and stirred at 25°C. The mixture was heated to 60°C under argon and stirred for 2 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction, the reaction solution was cooled to room temperature. The filtrate was filtered through celite and concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography using a 0% → 10% methanol / dichloromethane mobile phase as the elution agent. The resulting fraction was then evaporated to remove the solvent by vacuum rotary evaporation to obtain an atropisomer mixture of compounds 14-5a and 14-5b (white solid, 129 mg, 75%). Chiral HPLC (column: CHIRALPAK IK, 2 x 25 cm, 5 μm; mobile phase: methanol / methanolic ammonia solution = 100 / 0.1 (v / v), flow rate: 0.8 ml / min) yielded 43.5 mg of a faster peak, white solid compound 14-5a (retention time 9.933 min) and 34.6 mg of a slower peak, white solid compound 14-5b (retention time 10.847 min). MS (ESI, m / z): 1075.1 [M+H].

[0355] Step 5:

[0356] Under nitrogen protection and stirring at 25 degrees Celsius, compound 14-5a (the fast peak in step 4, 43.5 mg) and trifluoroacetic acid solution (5 ml) were added to the reaction flask in sequence. The mixture was heated to 60 degrees Celsius under argon protection at room temperature and stirred for 3 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain a crude product. The obtained crude product was purified by high-performance liquid chromatography to obtain compound 14a (yellow solid, 23 mg). MS (ESI, m / z): 735.3 [M+H] +.

[0357] 1 H NMR(400MHz, Methanol-d4)δ7.54(d,J=9.5Hz,1H),6.60(s,1H),5.39–5.24(m,2H),4.48–4.36(m,2H) ,4.31–4.18(m,2H),3.61(td,J=24.0,20.9,9.3Hz,5H),3.24–3.06(m,3H),2.86–2.72(m,3H),2.62(s, 1H),2.44(d,J=2.3Hz,2H),2.38(d,J=6.8Hz,1H),2.35–2.26(m,2H),2.24–2.15(m,2H),2.03(d,J=6.1 Hz,2H),1.81(d,J=15.7Hz,3H),1.74–1.56(m,4H),1.29(d,J=3.5Hz,4H),1.11(dd,J=6.3,4.2Hz,4H).

[0358] Compound 14b (yellow solid, 21 mg) was prepared from compound 14-5b (the slow peak from step 4, 34.6 mg) by the same procedure as step 5. MS (ESI, m / z): 735.3 [M+H] + .

[0359] 1H NMR(400MHz, Methanol-d4)δ6.73(d,J=10.1Hz,1H),5.79(s,1H),4.60–4.40(m,2H),3.61(t,J =14.5Hz,2H),3.51–3.38(m,2H),2.86–2.73(m,5H),2.46–2.29(m,3H),2.05–1.91(m,3H),1.8 2(s,1H),1.63(d,J=2.2Hz,3H),1.59–1.45(m,4H),1.41–1.36(m,1H),1.02(s,3H),0.87(dt,J =10.7,9.0Hz,3H),0.51(dd,J=20.9,6.4Hz,5H),0.30(dd,J=6.3,4.3Hz,5H),0.12–0.01(m,2H)

[0360] Example 15

[0361] Compound 15a and Compound 15b

[0362] The synthetic routes of compounds 15a and 15b are as follows:

[0363] Step 1:

[0364] To a solution of compound 8-1 (242 mg, 0.513 mmol, 1.0 eq) and compound 15-1 (200 mg, 0.769 mmol, 1.5 eq) in dioxane (8 ml) and water (1 ml) was added cesium carbonate (501 mg, 1.54 mmol, 3 eq). The mixture was purged with argon three times, and tetrakistriphenylphosphine palladium (237 mg, 0.204 mmol, 0.4 eq) was added. The mixture was heated to 110°C and stirred for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the solvent was removed by rotary evaporation under reduced pressure. The crude product was purified by silica gel column chromatography, eluting with a mobile phase of 0% → 10% petroleum ether / ethyl acetate over 20 minutes; UV detector: 254 / 220 nm; to afford compound 15-2 (pale yellow solid, 290 mg, 93% yield). MS (ESI, m / z): 609.3 [M+H] + .

[0365] Step 2:

[0366] Compound 15-2 (180 mg, 0.30 mmol, 1.0 eq), compound 3-5 (110 mg, 0.384 mmol, 1.3 eq), sodium hydroxide (23.6 mg, 0.591 mmol, 2 eq), and tetrahydrofuran solution (4 ml) were added sequentially to the reaction flask under nitrogen protection and stirring at 25°C. The mixture was heated to 60°C under argon protection and stirred for 2 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, the reaction solution was cooled to room temperature. The filtrate was filtered through celite and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a 0% → 10% methanol / dichloromethane mobile phase. The resulting fraction was evaporated to remove the solvent and obtain compound 15-3 (white solid, 165 mg, 64%). MS (ESI, m / z): 875.5 [M+H] + .

[0367] Step 3:

[0368] Compound 15-3 (white solid, 165 mg, 0.189 mmol, 1.0 eq) and 4N hydrochloric acid in dioxane solution (5 ml) were added sequentially to the reaction flask under nitrogen protection and stirring at 25 degrees Celsius. The mixture was stirred and reacted for 3 hours at room temperature under argon protection. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction, the reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was purified by chiral HPLC (column: CHIRALPAK OD, 2x25 cm, 5 μm; mobile phase: ethanol / methanol solution of ammonia = 100 / 0.1 (v / v), flow rate: 0.5 ml / min) to obtain 31 mg of the faster peak white solid compound 15a (retention time 9.545 min) and 29 mg of the slower peak white solid compound 15b (retention time 12.682 min).

[0369] Compound 15a, MS (ESI, m / z): 691.4 [M+H] + .

[0370] 1H NMR(400MHz, Methanol-d4)δ7.70–7.65(m,1H),7.59(d,J=7.7Hz,2H),7.43(d,J=8.7Hz,1H),5 .47–5.20(m,2H),4.51(d,J=12.8Hz,2H),4.35–4.21(m,2H),3.73–3.59(m,5H),3.39(d,J=6.7 Hz,1H),3.23(s,1H),3.15(d,J=14.2Hz,1H),2.87–2.73(m,3H),2.71–2.61(m,1H),2.44–2.32(m,3H),2.23–2.15(m,1H ),2.07–1.98(m,1H),1.91(s,4H),1.77–1.63(m,3H),1.60(s,1H),1.31(d,J=17.7Hz,4H),1.09(dd,J=6.3,2.7Hz,6H).

[0371] Compound 15b, MS (ESI, m / z): 691.4 [M+H] + .

[0372] 1 H NMR (400MHz, Methanol-d4) δ7.70–7.66(m,1H),7.63–7.56(m,2H),7.44(d,J=8.8Hz,1H),5.45–5.27(m ,2H),4.52(d,J=12.9Hz,2H),4.35–4.24(m,2H),3.75(s,2H),3.70–3.57(m,4H),3.41(s,1H),3.25(s, 1H),3.16(d,J=16.6Hz,1H),2.87–2.74(m,3H),2.70–2.61(m,1H),2.43–2.32(m,3H),2.17(s,1H),2.0 3(d,J=6.2Hz,1H),1.92(s,4H),1.76–1.57(m,4H),1.31(d,J=17.3Hz,3H),1.09(dd,J=6.3,4.3Hz,6H).

[0373] Example 16

[0374] 4-(3,9-diazabicyclo[4.2.1]nonan-3-yl)-2-((2R,6R,7aS)-2-((2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolidin-7a(5H)-methoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)-5-ethylnaphthol-2-ol

[0375] The synthetic route of compound 16 is as follows

[0376] Step 1: Synthesis of tert-butyl 3-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0377] Compound 16-1 (0.88 g, 3 mmol), compound 9-1 (680 mg, 3 mmol), and N,N-diisopropylethylamine (1.4 ml, 8.1 mmol) were added to 10 ml of dimethyl sulfoxide and stirred at room temperature overnight. 20 ml of water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate (2 x 30 ml). The organic layer was washed once with 20 ml of water, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. Purification by column chromatography (ethyl acetate:petroleum ether = 0-80%) afforded 1.36 g of compound 16-2 as a brown solid, in a 94% yield. LC-MS: m / z: (M+H)+ = 484.3.

[0378] Step 2: Synthesis of tert-butyl 3-(7-benzyl-2-(((2R,6R,7aS)-2-((2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolidin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0379] Compound 16-2 (350 mg, 0.72 mmol), compound 3-5 (210 mg, 0.73 mmol) (the compound represented by Formula 4), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (40 mg, 0.086 mmol), sodium tert-butoxide (150 mg, 1.56 mmol), and tris(dibenzylideneacetone)dipalladium (60 mg, 0.066 mmol) were added to 8 ml of toluene and stirred overnight at 110°C under argon. The reaction mixture was concentrated to obtain the crude product, which was then purified by column chromatography (methanol:dichloromethane = 0-15%) to afford compound 16-3 (230 mg, 43% yield) as a brown solid. LC-MS: m / z: (M+H)+ = 734.5.

[0380] Step 3: Synthesis of tert-butyl 3-(2-(((2R,6R,7aS)-2-(((2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0381] Compound 16-3 (230 mg, 0.31 mmol) and palladium hydroxide (35 mg, 0.05 mmol) were added to 10 ml of methanol and stirred overnight at room temperature under a hydrogen atmosphere. The mixture was filtered, concentrated, and purified by column chromatography (7 M ammonia methanol: dichloromethane = 0-15%) to afford 160 mg of compound 16-4 as a white solid in a 79% yield. LC-MS: m / z: (M+H) + =644.5.

[0382] Step 4: Synthesis of tert-butyl 3-(2-(((2R,6R,7aS)-2-(((2S,6R)-2,6-dimethylmorpholinyl)methylmethylmethyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-7-(8-ethyl-3-(methoxymethoxynaphthalen-1-yl)-5,6,7-8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,9-diazabicyclo[4.2.1]nonene-9-carboxylate

[0383] Compound 16-4 (120 mg, 0.186 mmol), compound 16-5 (100 mg, 0.34 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (20 mg, 0.04 mmol), cesium carbonate (150 mg, 0.46 mmol), and tris(dibenzylideneacetone)dipalladium (35 mg, 0.038 mmol) were added to 8 ml of toluene and stirred at 110°C overnight. The reaction mixture was filtered and concentrated to obtain the crude product, which was then purified by column chromatography (methanol:dichloromethane = 0-20%) to afford 70 mg of compound 16-6 as a brown solid, in a 43% yield. LC-MS: m / z: (M+H)+ = 858.5.

[0384] Step 5: Synthesis of 4-(4-(3,9-diazabicyclo[4.2.1]nonan-3-yl)-2-((2R,6R,7aS)-2-([(2S,6R)-2,6-dimethylmorpholinyl)methyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-5-ethylnaphth-2-ol

[0385] Compound 16-6 (50 mg, 0.058 mmol) was dissolved in 5 ml of 4 mol / L methanolic hydrochloric acid and stirred at room temperature for 1 hour. The reaction mixture was concentrated and made alkaline with saturated sodium bicarbonate solution. The mixture was then extracted with a mixture of methanol and dichloromethane (methanol:dichloromethane = 1:10). The organic layer was dried over anhydrous sodium sulfate and concentrated to obtain the crude product, which was separated and purified by thin-layer chromatography (4 M ammonia methanol:dichloromethane = 1:10) to afford compound 16 (10 mg, 24% yield) as a brown solid. LC-MS: m / z: (M+H)+ = 714.5.

[0386] 1 H NMR (400MHz, CDCl3) δ7.49–7.37(m,1H),7.28–7.20(m,1H),7.07(m,1H),6.98–6.72(m,2H),5.25(m,1H),4. 20–3.63(m,10H),3.51–2.99(m,9H),2.83–2.55(m,7H),2.44–1.96(m,10H),1.72(m,3H),1.17–1.09(m,9H).

[0387] Example 17

[0388] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2S,6R,7aS)-2-(2-((2S,6R)-2,6-dimethylmorpholinyl)ethyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

[0389] The synthetic route is as follows:

[0390] Step 1:

[0391] Under 25 degrees Celsius nitrogen protection stirring conditions, 17-1 (3.0 grams, 6.924 mmoles, 1.00 equivalents), anhydrous tetrahydrofuran (30 milliliters) and hexamethylphosphoric triamide (6 milliliters) were added sequentially to a 100 ml three-necked flask. Under -78 degrees Celsius nitrogen protection stirring conditions, a tetrahydrofuran solution of lithium diisopropylamide (1 mol per liter, 8.3 milliliters, 8.3 mmoles, 1.2 equivalents) was added dropwise to the reaction solution. The mixture was reacted under 78 degrees Celsius nitrogen protection stirring conditions for 0.5 hour. Subsequently, allyl bromide (1.06 grams, 8.309 mmoles, 1.2 equivalents) was added dropwise to the reaction solution under 78 degrees Celsius nitrogen protection stirring conditions. The mixture was slowly raised to 25 degrees Celsius and reacted under 25 degrees Celsius nitrogen protection stirring conditions for 2 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was slowly poured into a saturated ammonium chloride solution (100 ml) to quench the reaction, and the resulting mixture was extracted with ethyl acetate (100 ml x 3). The organic phases were combined and dried over anhydrous sodium sulfate. The desiccant was filtered to remove the solvent, and the filtrate was evaporated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography using a 0% → 50% methyl tert-butyl ether / petroleum ether mobile phase gradient elution. The resulting fractions were evaporated under reduced pressure to remove the solvent to obtain compound 17-2 (colorless oil, 1.09 g, 33% yield). MS(ESI,m / z):452.4[M+H]+; 1H NMR (400MHz, CDCl3) δ7.71–7.59(m,4H),7.50–7.36(m,6H),5.77–5.62(m,1H),5.47–5.31(m,1H),5.00–4.88(m,2H),4.21–4.03(m,1H),3.59 –3.51(m,1H),3.42–3.24(m,2H),2.75–2.64(m,1H),2.60–2.43(m,2H) ,2.18–2.06(m,2H),1.97–1.80(m,1H),1.76–1.70(m,1H),1.04(s,9H).

[0392] Step 2:

[0393] Under nitrogen protection and stirring at zero degrees Celsius, a solution of compound 17-2 (600 mg, 1.262 mmol, 1.00 eq) in anhydrous tetrahydrofuran (6 ml) was added dropwise with lithium aluminum tetrahydride in tetrahydrofuran (1 mol / L, 1.9 ml, 1.9 mmol, 1.5 eq). The mixture was reacted at 60 degrees Celsius under nitrogen protection and stirring for 2 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, the reaction solution was cooled to zero degrees Celsius, and water (1 ml), sodium hydroxide aqueous solution (15%, 1 ml), and water (3 ml) were added to the reaction solution in sequence. After stirring for 15 minutes, the insoluble matter was removed by filtration, and the filter cake was washed with tetrahydrofuran / methanol (3 / 1, 10 ml). The combined filtrate was evaporated under reduced pressure to remove the solvent to obtain a crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol (1 mol / L ammonia methanol solution) / dichloromethane mobile phase. The resulting fractions were evaporated to remove the solvent under reduced pressure to give compound 17-3 (colorless oil, 200 mg, 75% yield). MS(ESI,m / z):200.1[M+H]+; 1H NMR (400MHz, CDCl3) δ5.84–5.66(m,1H),5.35–5.13(m,1H),5.11–4.88(m,2H),3.40–3.13(m,4H),3.08–2.89(m,1H) ,2.69–2.60(m,1H),2.34–2.19(m,2H),2.18–2.08(m,3H),2.08–1.97(m,1H),1.98–1.88(m,1H),1.68–1.55(m,1H).

[0394] Step 3:

[0395] To a solution of compound 320-6 (3.44 g, 8.03 mmol) in anhydrous acetonitrile (20 ml) was added compound 17-3 (1.6 g, 8.04 mmol) and N,N-diisopropylethylamine (2.59 g, 20.1 mmol) in sequence under argon protection and stirring at 25 degrees Celsius. The resulting mixture was reacted at 80 degrees Celsius under argon protection and stirring for 60 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, water (25 ml) was added to the reaction solution to quench the reaction. The resulting mixture was extracted with ethyl acetate (25 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (30 ml x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica gel column chromatography using a 0% → 10% methanol / dichloromethane mobile phase gradient elution. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 17-4 (yellow solid, 3.18 g). MS (ESI, m / z): 591.3 [M+H]+ .

[0396] Step 4:

[0397] To a solution of compound 17-4 (3.18 g, 5.38 mmol) in tetrahydrofuran (30 mL) was added potassium phosphate (2.88 g, 13.9 mmol), compound 1-8 (3.48 g, 6.79 mmol), Ad2n-BuP-Pd-G3 (0.99 g, 1.36 mmol), and water (7 mL) in sequence under argon at 25°C. The mixture was stirred at 70°C under argon for 4 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature and quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (15 mL x 3). The organic phases were combined and washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 17-5 (yellow solid, 4.2 g). MS (ESI, m / z): 941.5 [M+H] + .

[0398] Step 5:

[0399] To a solution of compound 17-5 (2.3 g, 2.44 mmol) in dichloromethane (24 mL) was added potassium osmate dihydrate (0.23 g, 0.62 mmol), N-methylmorpholine N-oxide (1.49 g, 12.7 mmol), and water (6 mL) in sequence under argon at 25°C. The mixture was stirred at room temperature under argon for 16 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, sodium sulfite (15 mL) was added to quench the reaction. The resulting mixture was extracted with dichloromethane (15 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 17-6 (yellow solid, 1.7 g). MS (ESI, m / z): 976.5 [M+H] + .

[0400] Step 6:

[0401] To a solution of compound 17-6 (1.7 g, 1.7 mmol) in N,N-dimethylformamide (15 mL) was added cesium fluoride (0.65 g, 4.3 mmol) at 25°C under argon and stirring. The mixture was stirred at room temperature for 3 hours under argon. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion, aqueous ammonium chloride (10 mL) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined and washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol / dichloromethane. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 17-7 (yellow solid, 0.81 g). MS (ESI, m / z): 819.4 [M+H] + .

[0402] Step 7:

[0403] To a solution of compound 17-7 (169 mg, 0.21 mmol) in acetonitrile (8 mL) was added sodium periodate (88.4 mg, 0.41 mmol) and water (2 mL) at 25°C under argon protection and stirring. The mixture was stirred at room temperature for 15 minutes under argon protection. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, aqueous solution (5 mL) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (5 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (5 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain compound 17-8 (yellow solid, 158 mg). MS (ESI, m / z): 787.7 [M+H] + .

[0404] Step 8:

[0405] Compound 3-3 (32 mg, 0.28 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 17-8 (86 mg, 0.11 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 17-9 (white solid, 40 mg, 41.09% yield). MS (ESI, m / z): 886.4 [M+H] + .

[0406] Step 9:

[0407] Compound 17-9 (40 mg, 0.045 mmol) was dissolved in acetonitrile (1 mL) and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 17 (off-white solid, 25 mg, 74.53% yield). MS (ESI, m / z): 743.3 [M+H] + . 1H NMR(400MHz,MeOD)δ9.08(s,1H),8.46(s,2H),7.89(dd,J=9.1,5.7Hz,1H),7.44–7.30(m,2H),7.23(d,J=2.4Hz, 1H),5.51(s,0.5H),5.38(s,0.5H),4.77(d,J=10.6Hz,2H),4.45(dt,J=26.3,11.0Hz,2H),4.03(s,2H),3.87(s, 2H),3.71(s,2H),3.60(s,1H),3.47(d,J=14.8Hz,2H),3.36(s,1H),3.04–2.85(m,3H),2.60(t,J=7.5Hz,2H),2. 40(dd,J=39.1,15.9Hz,4H),2.08–1.91(m,5H),1.84(t,J=13.7Hz,1H),1.72(d,J=6.2Hz,2H),1.25–0.98(m,6H).

[0408] Example 18

[0409] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2S,6R,7aS)-2-(2-((2S,6R)-2,6-dimethylmorpholinyl)ethyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0410] The synthetic route is as follows:

[0411] Step 1:

[0412] To a solution of compound 17-4 (1.2 g, 2.03 mmol) in tetrahydrofuran (30 mL) was added potassium phosphate (2.1 g, 9.9 mmol), compound 3-8 (1.2 g, 3.3 mmol), Ad2n-BuP-Pd-G3 (0.4 g, 0.5 mmol), and water (7 mL) in sequence under argon at 25°C. The mixture was stirred at 70°C under argon for 4 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature and quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (15 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 18-1 (yellow solid, 1.2 g). MS (ESI, m / z): 789.9 [M+H] + .

[0413] Step 2:

[0414] To a solution of compound 18-1 (1.2 g, 1.5 mmol) in dichloromethane (24 ml) was added potassium osmate dihydrate (0.12 g, 0.33 mmol), N-methylmorpholine N-oxide (0.7 g, 6.0 mmol), and water (6 ml) in sequence under argon protection and stirring at 25 degrees Celsius. The mixture was stirred at room temperature under argon protection for 16 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, sodium sulfite (15 ml) was added to quench the reaction. The resulting mixture was extracted with dichloromethane (15 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 ml x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 18-2 (yellow solid, 1.2 g). MS (ESI, m / z): 823.9 [M+H] + .

[0415] Step 3:

[0416] Under argon protection and stirring at 25 degrees Celsius, sodium periodate (560 mg, 2.62 mmol) and water (6 ml) were added to a solution of compound 18-2 (1.2 g, 1.5 mmol) in acetonitrile (24 ml). The mixture was stirred at room temperature under argon protection for 15 minutes. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, aqueous solution (25 ml) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (25 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (5 ml x 1), then dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain compound 18-3 (yellow solid, 1.0 g). MS (ESI, m / z): 791.7 [M+H] + Step 4:

[0417] Compound 3-3 (32 mg, 0.28 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (80 mg, 0.10 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 18-4 (white solid, 40 mg, 44% yield). MS (ESI, m / z): 891.3 [M+H] + .

[0418] Step 5:

[0419] Compound 18-4 (40 mg, 0.045 mmol) was dissolved in acetonitrile (1 mL), and a 4M dioxane hydrochloride solution (1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 18 (white solid, 15 mg, 44.72% yield). MS (ESI, m / z): 747.3 [M+H]+.

[0420] 1H NMR (400MHz, MeOD) δ9.12(s,1H),8.43(d,J=9.1Hz,2H),7.71(dd,J=9.0,5.9Hz,1H),7.34(d,J=2.6Hz,1H),7.28(t,J= 9.3Hz,1H),7.07(d,J=2.4Hz,1H),5.50(s,0.5H),5.37(s,0.5H),4.74(d,J=15.0Hz,1H),4.44(dd,J=22.3,10.8Hz,2H) ,4.00(s,2H),3.92–3.80(m,2H),3.71(s,2H),3.58(s,01H),3.46(d,J=16.9Hz,2H),3.02–2.84(m,3H),2.58(s,2H),2 .54–2.39(m,4H),2.35(d,J=17.1Hz,1H),2.21(s,1H),2.09–1.66(m,9H),1.16(d,J=6.1Hz,6H),0.81(t,J=7.4Hz,3H).

[0421] Example 19

[0422] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,6S,7aS)-2-fluoro-6-(2-(4-(piperidin-1-ylmethyl)piperidin-1-yl)ethyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0423] The synthetic route is as follows:

[0424] Step 1:

[0425] Compound 19-1 (25 mg, 0.14 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (60 mg, 0.076 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 19-2 (white solid, 40 mg, 55.03% yield). MS (ESI, m / z): 958.3 [M+H] + .

[0426] Step 2:

[0427] Compound 19-2 (40 mg, 0.042 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 19 (white solid, 17 mg, 50.09% yield). MS (ESI, m / z): 812.8 [M+H] + .

[0428] 1H NMR(400MHz,MeOD)δ9.10(s,1H),8.50(s,2H),7.70(dd,J=9.0,5.8Hz,1H),7.37–7.22(m,2H),7.0 7(d,J=2.5Hz,1H),5.44(s,0.5H),5.30(s,0.5H),4.70(t,J=11.4Hz,2H),4.63–4.50(m,1H),4.40– 4.25(m,2H),3.88–3.75(m,3H),3.43(s,1H),3.17(d,J=15.6Hz,2H),2.83(dd,J=23.8,12.8Hz,5H ),2.73–2.62(m,2H),2.59–2.15(m,8H),1.91(dd,J=15.6,11.4Hz,5H),1.76(d,J=4.5Hz,5H),1.60 (s,2H),1.42(d,J=12.1Hz,2H),1.31(s,1H),0.81(t,J=7.4Hz,3H).

[0429] Example 20

[0430] Compound: 4-(1-(2-((2S,6R,7aS)-7a-(((4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)-6-fluorohexahydro-1H-pyrrolidin-2-yl)ethyl)piperidin-4-yl)benzamide

[0431] The synthetic route is as follows:

[0432] Step 1:

[0433] Compound 20-1 (30 mg, 0.15 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction mixture was stirred at 20°C for 10 minutes. Compound 18-3 (90 mg, 0.11 mmol) was added, and the reaction mixture was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction mixture was stirred at 20°C for 16 hours. The reaction mixture was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to afford compound 20-2 (white solid, 45 mg, 40.38% yield). MS (ESI, m / z): 979.3 [M+H] + .

[0434] Step 2:

[0435] Compound 20-2 (45 mg, 0.046 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 20 (white solid, 25 mg, 65.13% yield). MS (ESI, m / z): 835.3 [M+H] + .

[0436] 1H NMR (400MHz, MeOD) δ9.12(s,1H),8.50(s,2H),7.84(dd,J=8.1,3.6Hz,2H),7.70(dd,J=8.8,6.0Hz,1H),7.32(ddd,J=18.9,18 .0,8.3Hz,4H),7.07(d,J=2.4Hz,1H),5.47(s,0.5H),5.33(s,0.5H),4.76(t,J=13.6Hz,2H),4.38(dt,J=16.6,10.6Hz,2H),4 .00(s,2H),3.94–3.78(m,2H),3.60(d,J=11.2Hz,2H),3.50(s,1H),3.23(d,J=13.2Hz,1H),3.16–2.77(m,6H),2.49(s,3H),2 .40–2.30(m,1H),2.23(d,J=11.0Hz,1H),2.01(dd,J=29.2,15.6Hz,7H),1.85(d,J=30.5Hz,3H),0.81(dd,J=7.3,4.7Hz,3H).

[0437] Example 21

[0438] Compound: 4-(1-((1-(2-((2S,6R,7aS)-7a-(((4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl))-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)-6-fluorohexahydro-1H-pyrrolidin-2-yl)ethyl)piperidin-4-yl)methyl)piperidin-4-yl)benzamide

[0439] The synthetic route is as follows:

[0440] Step 1:

[0441] Compound 21-1 (42 mg, 0.14 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (90 mg, 0.11 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 21-1 (white solid, 50 mg, 40.82% yield). MS (ESI, m / z): 1076.3 [M+H] + .

[0442] Step 2:

[0443] Compound 21-2 (50 mg, 0.046 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 21 (white solid, 25 mg, 57.78% yield). MS (ESI, m / z): 466.8 [M / 2+H] + .

[0444] 1H NMR (400MHz, MeOD) δ9.12 (s, 1H), 8.38 (s, 3H), 7.85 (d, J = 8.2Hz, 1H), 7.75–7.66 (m, 1H), 7.41–7. 21(m,3H),7.07(d,J=2.5Hz,1H),5.45(s,0.5H),5.32(s,0.5H),4.76(s,2H),4.47–4.22(m,3H), 3.99(s,2H),3.83(dd,J=35.2,17.6Hz,4H),3.48(d,J=13.4Hz,2H),3.15(s,4H),3.00(s,2H),2. 79(s,4H),2.61–2.11(m,9H),2.08–1.68(m,9H),1.49(s,3H),1.31(s,3H),0.82(t,J=7.4Hz,3H).

[0445] Example 22

[0446] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,6S,7aS)-2-fluoro-6-(2-(4-(4-isopropylphenoxy)piperidin-1-yl)ethyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0447] The synthetic route is as follows:

[0448] Step 1:

[0449] Compound 22-1 (31 mg, 0.14 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction mixture was stirred at 20°C for 10 minutes. Compound 18-3 (60 mg, 0.076 mmol) was added, and the reaction mixture was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction mixture was stirred at 20°C for 16 hours. The reaction mixture was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to afford compound 22-2 (white solid, 35 mg, 46.33% yield). MS (ESI, m / z): 994.3 [M / 2+H]+.

[0450] Step 2:

[0451] Compound 22-2 (35 mg, 0.035 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 22 (white solid, 15 mg, 50.42% yield). MS (ESI, m / z): 850.7 [M+H]+.

[0452] 1H NMR(400MHz,MeOD)δ9.11(s,1H),8.49(s,2H),7.70(dd,J=9.1,5.8Hz,1H),7.38–7.23(m,2H),7.16(d,J=8.4Hz,2H),7.0 7(d,J=2.5Hz,1H),6.90(d,J=8.4Hz,2H),5.45(s,0.5H),5.32(s,0.5H),4.72(t,J=13.5Hz,2H),4.58(s,1H),4.42–4.27 (m,2H),3.85(dd,J=30.6,15.8Hz,4H),3.46(s,1H),3.24(dd,J=25.4,15.1Hz,3H),3.05(d,J=34.3Hz,4H),2.86(dt,J=1 3.9,7.0Hz,2H),2.53–2.30(m,4H),2.00(ddd,J=60.3,49.7,14.5Hz,12H),1.23(d,J=6.9Hz,6H),0.81(t,J=7.3Hz,3H).

[0453] Example 23

[0454] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,6S,7aS)-2-fluoro-6-(2-(9-methyl-3,9-diazaspiro[5.5]undec-3-yl)ethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethyl-6-fluoronaphthalen-2-ol

[0455] The synthetic route is as follows:

[0456] Step 1:

[0457] Compound 23-1 (34 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (60 mg, 0.075 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 23-2 (white solid, 30 mg, 42.42% yield). MS (ESI, m / z): 943.3 [M+H]+.

[0458] Step 2:

[0459] Compound 23-2 (30 mg, 0.032 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 23 (white solid, 11 mg, 43.02% yield). MS (ESI, m / z): 799.3 [M+H]+.

[0460] 1H NMR(400MHz,MeOD)δ9.14(s,1H),8.41(s,3H),7.71(dd,J=9.1,5.8Hz,1H),7.37–7.22(m,2H),7.06(d,J=2.2Hz ,1H),5.52(s,0.5H),5.38(s,0.5H),4.48(d,J=6.2Hz,2H),4.17(d,J=7.8Hz,2H),4.03–3.87(m,2H),3.61(d,J =6.0Hz,1H),3.46(dd,J=30.4,12.7Hz,2H),3.17(d,J=16.7Hz,7H),3.09(s,2H),2.92(s,1H),2.85(d,J=10.1H z,3H),2.58–2.29(m,5H),2.21(dd,J=13.0,6.1Hz,1H),2.15–2.01(m,4H),1.85(s,10H),0.81(t,J=7.4Hz,3H)

[0461] Example 24

[0462] Compound: 1-(2-((2S,6R,7aS)-7a-(((4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)-6-fluorohexahydro-1H-pyrrolidin-2-yl)ethyl)-3-methylpiperidin-3-ol

[0463] The synthetic route is as follows:

[0464] Step 1:

[0465] Compound 24-1 (25 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (60 mg, 0.075 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 24-2 (white solid, 35 mg, 51.74% yield). MS (ESI, m / z): 902.3 [M / 2+H]+.

[0466] Step 2:

[0467] Compound 24-2 (35 mg, 0.039 mmol) was dissolved in acetonitrile (1 mL), and a 4M dioxane hydrochloride solution (1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 24 (white solid, 12 mg, 42.26% yield). MS (ESI, m / z): 758.3 [M+H]+.

[0468] 1H NMR(400MHz,MeOD)δ9.11(s,1H),8.38(s,2H),7.71(dd,J=9.1,5.8Hz,1H),7.36–7.23(m,2H),7.0 6(d,J=2.4Hz,1H),5.45(s,0.5H),5.31(s,0.5H),4.74(d,J=15.7Hz,2H),4.56(s,1H),4.41–4.26( m,2H),4.02(s,2H),3.93–3.81(m,2H),3.66(t,J=8.1Hz,2H),3.43(d,J=9.9Hz,4H),3.25–3.11(m, 2H),2.89–2.82(m,1H),2.55–2.28(m,5H),2.23–1.75(m,12H),1.31(s,2H),0.81(t,J=7.3Hz,3H).

[0469] Example 25

[0470] Compound: 1-(2-((2S,6R,7aS)-7a-(((4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)-6-fluorohexahydro-1H-pyrrolidin-2-yl)ethyl)-3-methylpiperidin-3-ol

[0471] The synthetic route is as follows:

[0472] Step 1:

[0473] Compound 25-1 (23 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (60 mg, 0.075 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 25-2 (white solid, 30 mg, 44.94% yield). MS (ESI, m / z): 891.3 [M / 2+H]+.

[0474] Step 2:

[0475] Compound 25-2 (30 mg, 0.034 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 25 (white solid, 5 mg, 19.69% yield). MS (ESI, m / z): 747.3 [M+H]+.

[0476] 1H NMR(400MHz,MeOD)δ9.11(s,1H),8.40(s,3H),7.71(dd,J=9.1,5.9Hz,1H),7.39–7.23(m,2H),7.06(d, J=2.6Hz,1H),5.45(s,0.5H),5.32(s,0.5H),4.83–4.69(m,2H),4.63–4.48(m,1H),4.40–4.23(m,2H), 3.99(s,2H),3.93–3.78(m,2H),3.14(ddd,J=36.8,22.0,10.7Hz,4H),2.93–2.78(m,3H),2.54–2.10(m ,7H),2.07–1.94(m,3H),1.78(s,4H),1.64–1.46(m,2H),1.30(d,J=11.2Hz,3H),0.81(t,J=7.4Hz,3H).

[0477] Example 26

[0478] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,6S,7aS)-2-fluoro-6-(2-(piperazin-1-yl)ethyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethylnaphthalen-2-ol

[0479] The synthetic route is as follows:

[0480] Step 1:

[0481] To a solution of compound 17-4 (800 mg, 1.53 mmol) in tetrahydrofuran (30 mL) was added potassium phosphate (1.7 g, 8.0 mmol), compound 2-2 (870 mg, 2.5 mmol), Ad2n-BuP-Pd-G3 (0.25 g, 0.34 mmol), and water (7 mL) in sequence under argon at 25°C. The mixture was stirred at 70°C under argon for 4 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature and quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (15 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 26-1 (yellow solid, 0.8 g). MS (ESI, m / z): 771.9 [M+H] + .

[0482] Step 2:

[0483] To a solution of compound 26-1 (0.8 g, 1.0 mmol) in dichloromethane (24 ml) was added potassium osmate dihydrate (0.12 g, 0.33 mmol), N-methylmorpholine N-oxide (0.7 g, 6.0 mmol), and water (6 ml) in sequence under argon at 25 degrees Celsius. The mixture was stirred at room temperature under argon for 16 hours. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, sodium sulfite (15 ml) was added to quench the reaction. The resulting mixture was extracted with dichloromethane (15 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 ml x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 26-2 (yellow solid, 0.75 g). MS (ESI, m / z): 805.9 [M+H] + .

[0484] Step 3:

[0485] Under argon protection and stirring at 25 degrees Celsius, sodium periodate (374 mg, 1.75 mmol) and water (4 ml) were added to a solution of compound 26-2 (750 mg, 0.93 mmol) in acetonitrile (16 ml). The mixture was stirred at room temperature under argon protection for 15 minutes. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, aqueous solution (5 ml) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (5 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (5 ml x 1), then dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain compound 26-3 (yellow solid, 750 mg). MS (ESI, m / z): 773.7 [M+H] + .

[0486] Step 4:

[0487] Compound 26-4 (37 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 26-3 (60 mg, 0.078 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 26-5 (white solid, 35 mg, 47.57% yield). MS (ESI, m / z): 943.3 [M+H]+.

[0488] Step 5:

[0489] Compound 26-5 (35 mg, 0.037 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 26 (white solid, 10 mg, 38.67% yield). MS (ESI, m / z): 699.2 [M+H]+.

[0490] 1H NMR (400MHz, MeOD) δ9.11(s,1H),8.42(s,3H),7.66(d,J=8.3Hz,1H),7.46–7.29(m,2H),7.19(d,J=6.9Hz ,1H),7.02(d,J=2.6Hz,1H),5.51(s,0.5H),5.38(s,0.5H),4.73(s,1H),4.46(dd,J=25.0,11.1Hz,2H),4 .05(s,2H),3.95–3.79(m,2H),3.61(s,1H),3.46(dd,J=28.5,11.4Hz,2H),3.23–3.14(m,3H),2.96–2.87 (m,1H),2.69(s,3H),2.58–2.24(m,7H),2.13–1.78(m,5H),1.68(d,J=7.3Hz,2H),0.91(t,J=7.3Hz,3H).

[0491] Example 27

[0492] Compound: 1-(2-((2S,6R,7aS)-7a-(((4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)-6-fluorohexahydro-1H-pyrrolidin-2-yl)ethyl)piperidin-4-ol

[0493] The synthetic route is as follows:

[0494] Step 1:

[0495] Compound 27-1 (20 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 18-3 (60 mg, 0.075 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 27-2 (white solid, 30 mg, 45.66% yield). MS (ESI, m / z): 876.3 [M+H]+.

[0496] Step 2:

[0497] Compound 27-2 (30 mg, 0.034 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 27 (white solid, 5 mg, 20.09% yield). MS (ESI, m / z): 732.3 [M+H]+.

[0498] 1H NMR (400MHz, MeOD) δ9.13 (s, 1H), 8.55 (s, 3H), 7.71 (dd, J = 8.9, 5.8Hz, 1H), 7.3 9–7.21(m,2H),7.07(s,1H),5.51(s,0.5H),5.38(s,0.5H),4.45(s,2H),4.17( s,2H),3.96(s,3H),3.60(s,1H),3.44(dd,J=34.6,18.8Hz,4H),3.23–2.99(m, 4H), 2.92 (s, 1H), 2.62–2.26 (m, 5H), 2.24–1.66 (m, 12H), 0.81 (t, J = 7.2Hz, 3H).

[0499] Example 28

[0500] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,6S,7aS)-2-fluoro-6-(2-(3-(hydroxymethyl)piperazin-1-yl)ethyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-2-ethylnaphthol

[0501] The synthetic route is as follows:

[0502] Step 1:

[0503] Compound 28-1 (43 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction mixture was stirred at 20°C for 10 minutes. Compound 26-3 (60 mg, 0.078 mmol) was added, and the reaction mixture was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction mixture was stirred at 20°C for 16 hours. The reaction mixture was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to afford compound 28-2 (white solid, 25 mg, 32.94% yield). MS (ESI, m / z): 973.9 [M+H]+.

[0504] Step 2:

[0505] Compound 28-2 (25 mg, 0.026 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 28 (white solid, 5 mg, 26.38% yield). MS (ESI, m / z): 729.3 [M+H]+.

[0506] 1H NMR(400MHz,MeOD)δ9.12(s,1H),8.61(s,3H),7.66(d,J=8.1Hz,1H),7.45–7.29(m,2H),7.19(d,J=6.9Hz,1H ),7.03(s,1H),5.56(s,0.5H),5.43(s,0.5H),4.78(s,1H),4.52(s,2H),4.13(s,2H),3.93(dd,J=26.3,13.6 Hz,2H),3.82–3.67(m,3H),3.65–3.41(m,3H),3.20–3.03(m,3H),2.94(d,J=10.6Hz,2H),2.72(s,1H),2.66– 2.22(m,8H),2.03(t,J=26.2Hz,4H),1.87(d,J=12.3Hz,1H),1.68(s,2H),1.31(s,1H),0.91(t,J=7.3Hz,3H).

[0507] Example 29

[0508] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,6S,7aS)-2-fluoro-6-(2-(4-(piperidin-4-ylmethyl)piperidin-1-yl)ethyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethylnaphth-2-ol

[0509] The synthetic route is as follows:

[0510] Step 1:

[0511] Compound 29-1 (56 mg, 0.20 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 26-3 (60 mg, 0.078 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 29-2 (white solid, 20 mg, 24.69% yield). MS (ESI, m / z): 520.3 [M / 2+H]+.

[0512] Step 2:

[0513] Compound 29-2 (20 mg, 0.019 mmol) was dissolved in acetonitrile (1 mL), and a 4M dioxane hydrochloride solution (1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the crude product was purified by preparative HPLC to afford the formate salt of compound 29 (white solid, 10 mg, 66.12% yield). MS (ESI, m / z): 796.0 [M+H]+.

[0514] 1H NMR(400MHz,MeOD)δ9.13(s,1H),8.41(s,1H),7.66(d,J=7.9Hz,1H),7.42–7.36(m,1H),7.33(d,J=2.6Hz,1H),7.19(d,J=7.0Hz, 1H),7.03(s,1H),5.55(s,0.5H),5.42(s,0.5H),4.52(s,2H),4.21(d,J=12.0Hz,2H),3.98(dt,J=31.6,19.9Hz,3H),3.68(d,J=9. 9Hz,2H),3.61–3.48(m,4H),3.39(d,J=12.8Hz,2H),3.16(s,2H),2.99(s,5H),2.56(d,J=11.0Hz,2H),2.49(s,1H),2.43–2.25(m, 4H), 2.12 (d, J = 9.7Hz, 4H), 1.96 (t, J = 14.4Hz, 8H), 1.74 (s, 2H), 1.51 (d, J = 11.9Hz, 3H), 1.42–1.26 (m, 7H), 0.90 (d, J = 7.4Hz, 3H).

[0515] Example 30

[0516] Compound: (2S,6R)-4-(2-((2S,6R,7aS)-7a-(((4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl))-8-fluoro-7-(6-fluoro-5-methyl-1H-indazol-4-yl)pyrido[4,3-d]pyrimidin-2-yl)oxy)methyl)-6-fluorohexahydro-1H-pyrrolidin-2-yl)ethyl)-2,6-dimethylmorpholine

[0517] The synthetic route is as follows:

[0518] Step 1:

[0519] To a solution of compound 17-4 (100 mg, 0.17 mmol) in tetrahydrofuran (5 mL) was added potassium phosphate (212 mg, 1.0 mmol), compound 30-1 (86 mg, 0.31 mmol), Ad2n-BuP-Pd-G3 (100 mg, 0.14 mmol), and water (1 mL) in sequence under argon at 25°C. The mixture was stirred at 70°C under argon for 4 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature and quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (15 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 30-2 (yellow solid, 80 mg). MS (ESI, m / z): 705.3 [M+H] + .

[0520] Step 2:

[0521] To a solution of compound 30-2 (80 mg, 0.11 mmol) in dichloromethane (4 mL) was added potassium osmate dihydrate (12 mg, 0.033 mmol), N-methylmorpholine N-oxide (70 mg, 0.6 mmol), and water (1 mL) in sequence at 25°C under argon. The mixture was stirred at room temperature for 16 hours under argon. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion, sodium sulfite (15 mL) was added to quench the reaction. The resulting mixture was extracted with dichloromethane (15 mL x 3). The organic phases were combined and washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol / dichloromethane. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 30-3 (yellow solid, 75 mg). MS (ESI, m / z): 739.3 [M+H] + .

[0522] Step 3:

[0523] Under argon protection and stirring at 25 degrees Celsius, sodium periodate (374 mg, 1.75 mmol) and water (4 ml) were added to a solution of compound 30-3 (60 mg, 0.081 mmol) in acetonitrile (16 ml). The mixture was stirred at room temperature under argon protection for 15 minutes. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, aqueous solution (5 ml) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (5 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (5 ml x 1), then dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain compound 30-4 (yellow solid, 60 mg). MS (ESI, m / z): 773.7 [M+H] + .

[0524] Step 4:

[0525] Compound 3-3 (32 mg, 0.28 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 30-4 (60 mg, 0.085 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 30-5 (white solid, 25 mg, 36.49% yield). MS (ESI, m / z): 806.3 [M+H]+.

[0526] Step 5:

[0527] Compound 30-5 (25 mg, 0.031 mmol) was dissolved in acetonitrile (1 mL), and a 4M dioxane hydrochloride solution (1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 30 (off-white solid, 10 mg, 45.62% yield). MS (ESI, m / z): 707.3 [M+H]+.

[0528] 1H NMR (400MHz, MeOD) δ9.23 (s, 1H), 8.41 (s, 2H), 7.74 (s, 1H), 7.42 (d, J = 9.7Hz, 1H), 5.57 (s, 0.5 H),5.44(s,0.5H),4.54(s,2H),4.17(s,2H),3.97(d,J=12.1Hz,2H),3.76(d,J=5.7Hz,3H),3.6 4–3.48(m,2H),3.12(d,J=11.6Hz,2H),2.99(t,J=9.9Hz,1H),2.77(t,J=7.1Hz,2H),2.45(dd, J=24.3,14.4Hz,4H),2.26(s,3H),2.20–2.02(m,6H),1.97–1.76(m,3H),1.19(d,J=5.4Hz,6H).

[0529] Example 31

[0530] Compound: 7-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2S,6R,7aS)-2-(2-((2S,6R)-2,6-dimethylmorpholinyl)ethyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)benzo[d]2-thiazolamine

[0531] The synthetic route is as follows:

[0532] Step 1:

[0533] To a solution of compound 17-4 (100 mg, 0.17 mmol) in tetrahydrofuran (5 mL) was added potassium phosphate (213 mg, 1.0 mmol), compound 31-1 (113 mg, 0.3 mmol), Ad2n-BuP-Pd-G3 (31 mg, 0.043 mmol), and water (1 mL) in sequence under argon at 25°C. The mixture was stirred at 70°C under argon for 4 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature and quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (15 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 31-2 (yellow solid, 75 mg). MS (ESI, m / z): 805.3 [M+H] + .

[0534] Step 2:

[0535] To a solution of compound 31-2 (75 mg, 0.093 mmol) in dichloromethane (4 mL) was added potassium osmate dihydrate (12 mg, 0.033 mmol), N-methylmorpholine N-oxide (70 mg, 0.6 mmol), and water (1 mL) in sequence at 25°C under argon. The mixture was stirred at room temperature for 16 hours under argon. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion, sodium sulfite (15 mL) was added to quench the reaction. The resulting mixture was extracted with dichloromethane (15 mL x 3). The organic phases were combined and washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol / dichloromethane. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 31-3 (yellow solid, 70 mg). MS (ESI, m / z): 839.3 [M+H] + .

[0536] Step 3:

[0537] Under argon protection and stirring at 25 degrees Celsius, sodium periodate (37 mg, 0.17 mmol) and water (1 ml) were added to a solution of compound 31-3 (70 mg, 0.083 mmol) in acetonitrile (4 ml). The mixture was stirred at room temperature under argon protection for 15 minutes. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, aqueous solution (5 ml) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (5 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (5 ml x 1), then dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain compound 31-4 (yellow solid, 0.50 mg). MS (ESI, m / z): 807.3 [M+H] + .

[0538] Step 4:

[0539] Compound 3-3 (16 mg, 0.14 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 31-4 (50 mg, 0.062 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 31-5 (white solid, 30 mg, 53.41% yield). MS (ESI, m / z): 906.4 [M+H]+.

[0540] Step 5:

[0541] Compound 31-5 (30 mg, 0.033 mmol) was dissolved in acetonitrile (1 mL), and a 4M dioxane hydrochloride solution (1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the crude product was purified by preparative HPLC to afford the formate salt of compound 31 (white solid, 15 mg, 64.29% yield). MS (ESI, m / z): 707.3 [M+H]+.

[0542] 1H NMR (400MHz, MeOD) δ9.20 (s, 1H), 8.42 (s, 2H), 7.92 (d, J = 7.7Hz, 1H), 7.57–7.41 (m, 2H), 5.55 (s, 0.5H), 5. 42(s,0.5H),4.78(d,J=12.1Hz,2H),4.49(dd,J=22.3,11.3Hz,2H),4.08(s,2H),3.95–3.84(m,2H),3.79– 3.64(m,3H),3.53(dd,J=27.2,10.2Hz,2H),3.37(s,1H),3.07–2.91(m,3H),2.66(t,J=7.8Hz,2H),2.55–2 .34(m,4H),2.09–1.97(m,5H),1.87(d,J=14.7Hz,1H),1.78(d,J=6.8Hz,2H),1.16(dt,J=13.1,6.5Hz,6H).

[0543] Example 32

[0544] Compound: 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(((2S,6R,7aS)-2-(2-((2S,6R)-2,6-dimethylmorpholinyl)ethyl)-6-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)-8-fluoropyrido[4,3-d]pyrimidin-7-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

[0545] The synthetic route is as follows:

[0546] Step 1:

[0547] To a solution of compound 17-4 (100 mg, 0.19 mmol) in tetrahydrofuran (5 mL) was added potassium phosphate (210 mg, 1.0 mmol), compound 32-1 (110 mg, 0.26 mmol), Ad2n-BuP-Pd-G3 (31 mg, 0.043 mmol), and water (1 mL) in sequence under argon at 25°C. The mixture was stirred at 70°C under argon for 4 hours. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion of the reaction, the reaction solution was cooled to room temperature and quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (15 mL x 3), and the organic phases were combined; the organic phases were washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% to 10% methanol / dichloromethane as the mobile phase. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 32-2 (yellow solid, 100 mg). MS (ESI, m / z): 847.3 [M+H] + .

[0548] Step 2:

[0549] To a solution of compound 32-2 (100 mg, 0.12 mmol) in dichloromethane (4 mL) was added potassium osmate dihydrate (12 mg, 0.033 mmol), N-methylmorpholine N-oxide (70 mg, 0.6 mmol), and water (1 mL) in sequence at 25°C under argon. The mixture was stirred at room temperature for 16 hours under argon. The reaction progress was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After completion, sodium sulfite (15 mL) was added to quench the reaction. The resulting mixture was extracted with dichloromethane (15 mL x 3). The organic phases were combined and washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient elution of 0% → 10% methanol / dichloromethane. The resulting fraction was evaporated to remove the solvent under reduced pressure to obtain compound 32-3 (yellow solid, 90 mg). MS (ESI, m / z): 881.3 [M+H] + .

[0550] Step 3:

[0551] Sodium periodate (37 mg, 0.17 mmol) and water (1 ml) were added to a solution of compound 32-3 (90 mg, 0.10 mmol) in acetonitrile (4 ml) under argon protection and stirring at 25 degrees Celsius. The mixture was stirred at room temperature under argon protection for 15 minutes. The reaction process was monitored by liquid chromatography-mass spectrometry and thin-layer chromatography. After the reaction was completed, aqueous solution (5 ml) was added to quench the reaction. The resulting mixture was extracted with ethyl acetate (5 ml x 3), and the organic phases were combined; the organic phases were washed with saturated brine (5 ml x 1), then dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain compound 32-4 (yellow solid, 90 mg). MS (ESI, m / z): 849.3 [M + H] + .

[0552] Step 4:

[0553] Compound 3-3 (16 mg, 0.14 mmol) was dissolved in methanol (10 mL), and sodium acetate (75 mg, 0.92 mmol) was added. The reaction solution was stirred at 20°C for 10 minutes. Compound 32-4 (90 mg, 0.11 mmol) was added, and the reaction solution was stirred at 20°C for 30 minutes. Sodium cyanoborohydride (22 mg, 0.34 mmol) was added, and the reaction solution was stirred at 20°C for 16 hours. The reaction solution was diluted with dichloromethane (30 mL), washed with water (10 mL x 2) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified on a preparative plate (dichloromethane:methanol = 0-10%) to obtain compound 32-5 (yellow solid, 30 mg, 28.77% yield). MS (ESI, m / z): 948.3 [M+H]+.

[0554] Step 5:

[0555] Compound 32-5 (30 mg, 0.032 mmol) was dissolved in acetonitrile (1 mL), and a dioxane hydrochloride solution (4 M, 1 mL, 4 mmol) was added at 20°C. The reaction mixture was stirred at 20°C for 1 hour, filtered, and the resulting crude product was purified by preparative HPLC to afford the formate salt of compound 32 (orange solid, 10 mg, 41.72% yield). MS (ESI, m / z): 749.8 [M+H]+.

[0556] 1H NMR(400MHz,MeOD)δ9.14(s,1H),8.31(s,2H),7.45(dd,J=8.4,5.1Hz,1H),7.13–7.02(m,1H) ,5.58(s,0.5H),5.46(s,0.5H),4.59(d,J=12.3Hz,2H),4.19(s,2H),4.01–3.88(m,2H),3.77( d,J=6.6Hz,3H),3.70–3.53(m,2H),3.12(d,J=11.9Hz,2H),3.07–2.98(m,1H),2.76(dd,J=18. 3,11.1Hz,2H),2.47(dd,J=33.4,19.5Hz,4H),2.21–1.72(m,9H),1.19(dd,J=6.1,1.9Hz,6H).

[0557] Effect embodiment A:

[0558] 1. Experimental purpose:

[0559] A drug screening system based on the binding of KRAS_G12D and cRAF was used to detect the inhibitory ability of small molecule compounds on the binding activity of KRAS_G12D and cRAF.

[0560] 2. Experimental materials and equipment:

[0561] 3 Experimental methods

[0562] 3.1 Experimental steps:

[0563] a) BI-2852 was used as a positive control. The stock solution was diluted 3-fold to the first dilution point, followed by dilutions 10+0. Similarly, the test compound was diluted 3-fold to the first dilution point, followed by dilutions 11+0. Using an Echo, transfer 0.2 μL of the serially diluted compound solution to a 384-well plate. Duplicate wells were prepared for each compound, with a final DMSO concentration of 1%. Centrifuge at 1000 rpm / min for 1 min. The final concentrations of the positive control were 100, 33.33, 11.11, 3.70, 1.23, 0.412, 0.137, 0.046, 0.015, 0.005, and 0 μM. The final concentrations of the test compound were 200, 66.67, 22.22, 7.41, 2.47, 0.27, 0.091, 0.03, 0.0152, 0.01, and 0 μM.

[0564] b) Prepare KRAS_G12D in the kit with a final concentration of 10 μM GTP in diluent, transfer 5 μL to a 384-well reaction plate, and centrifuge at 1000 rpm / min for 1 minute.

[0565] c) Transfer 5 μL of the cRAF mixture to a 384-well plate, centrifuge at 1000 rpm / min for 1 min, and incubate at 25°C for 15 min.

[0566] d) Transfer 10 μL of the assay mixture to a 384-well plate, centrifuge at 1000 rpm for 1 min, and incubate at 4°C overnight.

[0567] e) Read the sample using an Envision multi-function plate reader at an excitation wavelength of 665 nm and an emission wavelength of 615 nm. The 665 / 615 ratio signal intensity is used to indicate enzyme activity.

[0568] f) Analyze the raw data.

[0569] 3.2 Experimental data processing method:

[0570] Fitting compound IC values ​​using Graphpad Prism 8 nonlinear regression equations 50 :

[0571] Negative control: DMSO

[0572] Positive control: 100 μM BI-2852

[0573] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (half inhibitory concentration): Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)*HillSlope))

[0574] X: log value of compound concentration

[0575] Y:665 / 615Ratio

[0576] The experimental results are shown in Tables 1-1 and 1-2 below:

[0577] Table 1-1

[0578] 3. Experimental Methods

[0579] 3.1 Experimental steps:

[0580] a) MRTX1133 was used as a positive control. 1 μM was the first dilution point. Three-fold dilutions were performed, with dilutions of 11+0 points. Similarly, the first dilution point for the test compound was 1 μM. Three-fold dilutions were performed, with dilutions of 11+0 points. Transfer 2 μL of the serially diluted compound solution to a 384-well plate. Each compound was plated in duplicate, with a final DMSO concentration of 1%. Centrifuge at 1000 rpm / min for 1 min. The final concentrations of the positive control were 1000, 333.3, 111.1, 37.03, 12.34, 4.12, 1.37, 0.45, 0.15, 0.05, and 0 nM. The final concentrations of the test compound were 1000, 333.3, 111.1, 37.03, 12.34, 4.12, 1.37, 0.45, 0.15, 0.05, and 0 nM.

[0581] b) Prepare KRAS_G12D in the kit with a final concentration of 10 μM GTP in diluent, transfer 5 μL to a 384-well reaction plate, and centrifuge at 1000 rpm / min for 1 minute.

[0582] c) Transfer 5 μL of the cRAF mixture to a 384-well plate, centrifuge at 1000 rpm / min for 1 min, and incubate at 25°C for 15 min.

[0583] d) Transfer 8 μL of the assay mixture to a 384-well plate, centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 4 h.

[0584] e) Read the sample using an Envision multi-function plate reader at an excitation wavelength of 665 nm and an emission wavelength of 615 nm. The 665 / 615 ratio signal intensity is used to indicate enzyme activity.

[0585] f) Analyze the raw data.

[0586] 3.2 Experimental data processing method:

[0587] Compound IC was fitted using Graphpad Prism 8 nonlinear regression equations. 50 :

[0588] Negative control: DMSO

[0589] Positive control: 1 μM MRTX1133

[0590] The IC50 (half maximal inhibitory concentration) of the compound was obtained using the following nonlinear fitting formula: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC50-X)*HillSlope))

[0591] X: log value of compound concentration

[0592] Y:665 / 615Ratio

[0593] The experimental results are shown in Table 1-2 below:

[0594] Table 1-2

[0595] Effect embodiment B:

[0596] pERK detection (In Cell Western):

[0597] 1 Experimental purpose:

[0598] The inhibitory ability of small molecule compounds on pERK in cells was detected by an in-cell Western-based drug screening method.

[0599] 2 Experimental materials and equipment:

[0600] 3 Experimental methods:

[0601] 3.1 Experimental steps:

[0602] a) On day 1, 6000 cells / well / 40 μL were seeded in a 384-well plate and incubated overnight at 37°C in a 5% CO2 incubator.

[0603] b) On day 2, 200 nL of serially diluted compounds (final 0.5% dimethyl sulfoxide) were added via Echo 550 and the cells were incubated at 37°C, 5% CO2 for 3 hours;

[0604] c) Apricot fix the cells with 40 μL / well 8% fixative and incubate at RT for 20 minutes;

[0605] d) Wash once with 40 μL PBS, permeabilize cells with 40 μL / well cold 100% methanol, and incubate at room temperature for 10 minutes;

[0606] e) Wash once with 40 μL / well PBS;

[0607] f) Add 20 μL / well Li-Cor blocking buffer and incubate at RT for 1 hour;

[0608] g) Remove the blocking buffer and add 20 μL / well of primary antibody mixture, rabbit anti-pERK (1:1000) and mouse anti-GAPDH (1:2000), and incubate overnight at 4°C.

[0609] h) On day 3, wash with 40 μL / well PBST (containing 0.05% Tween-20), soaking for 2 minutes each time, for a total of 3 times;

[0610] i) Add 20 μL / well of secondary antibody mixture, goat anti-rabbit 800CW (1:2000) and goat anti-mouse 680RD (1:20000), and incubate at room temperature for 45 minutes in the dark;

[0611] j) Wash with 40 μL / well PBST, soaking for 2 minutes each time, for a total of 3 times;

[0612] k) Centrifuge the plate upside down at 1000 rpm for 1 minute and scan the plate using an Odyssey CLx;

[0613] 3.2 Experimental data processing method:

[0614] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (50% inhibitory concentration): Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope))

[0615] X: Log value of cpd concentration

[0616] Y: Mean (relative pERK)

[0617] The experimental results are shown in Table 2-1:

[0618] Table 2-1

[0619] pERK detection (In Cell Western):

[0620] 1 Experimental purpose:

[0621] The inhibitory ability of small molecule compounds on pERK in cells was detected by HTRF-based drug screening method.

[0622] 2 Experimental materials and equipment:

[0623] 3 Experimental methods:

[0624] 3.1 Experimental steps:

[0625] a) Cell collection: Take cells in the logarithmic growth phase, discard the old culture medium, add 10 ml PBS to wash once, then add 2 ml trypsin to digest for the corresponding time, centrifuge (800 rpm, 5 min), remove the supernatant, and add 4 ml fresh culture medium to resuspend;

[0626] b) Cell counting: Take 20 μl of the cell suspension and mix with an equal volume of trypan blue; count the cells.

[0627] c) Cell seeding plate: Take the prepared cell suspension and add 90 μl / well (about 5×10 4 cells / well) were seeded into a 96-well plate (60 wells, 2 replicates), and culture medium was added as a blank control; the 96-well plate was placed in a 37° C., 5% CO 2 incubator for overnight culture.

[0628] d). Gradual dilution of the test compound

[0629] e). Compound treatment

[0630] The prepared concentration gradient compounds were added to the corresponding cell plate wells at 10 μl / well. Equal volumes of the corresponding culture medium solution were added to both the control and blank groups. The 96-well cell culture plates were then incubated at 37°C for 1 hour.

[0631] f). Prepare buffer solution:

[0632] (1) Dilute "lysis buffer 4X" 4 times with distilled water to prepare lysis buffer 1X;

[0633] (2) Acceptor antibody: diluted in detection buffer (ratio 1:19).

[0634] (3) Cryptate antibody: diluted in detection buffer (ratio 1:19).

[0635] (4) The two antibodies were pre-mixed at a ratio of 1:1.

[0636] (5)0Supplemented lysis buffer: Dilute "blocking reagent" 100 times with "lysis buffer 1X".

[0637] g). After the cells were treated with the compound for 1 hour, the culture dish was tapped to remove the cell supernatant.

[0638] h). Immediately add 50 μL of Supplemented lysis buffer (1X) and incubate at room temperature with shaking for at least 30 minutes.

[0639] i). After mixing by pipetting up and down, transfer 16 μL of cell lysate from the 96-well cell culture plate to the HTRF 96-well assay plate.

[0640] j) Add 4 μL (vol / vol) of the prepared antibody premix to the assay buffer. Cover the plate with a sealer. Incubate at room temperature for 4 hours (protect from light).

[0641] k). The maximum signal is reached after the incubation time and remains stable for 24 hours. Set up to read the fluorescence emission at two different wavelengths (665nm and 620nm).

[0642] l). Add positive control: 16 μL control lysate

[0643] m). Add Blank: 16μL Supplemented lysis buffer (1X)

[0644] Add Control: 16 μL untreated cell lysate

[0645] 3.2 Experimental data processing method:

[0646] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (50% inhibitory concentration): Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope))

[0647] X: Log value of cpd concentration

[0648] Y: Mean (relative pERK)

[0649] The experimental results are shown in Table 2-2:

[0650] Table 2-2

[0651] Effect embodiment C:

[0652] 3D CTG proliferation assay:

[0653] 1. Experimental purpose:

[0654] The inhibitory ability of small molecule compounds on cell proliferation was detected by 3D proliferation method.

[0655] 2. Experimental materials and equipment:

[0656] 3 Experimental methods:

[0657] 3.1 Experimental steps:

[0658] a) On day 1, cells were plated into 384-well 3D proliferation assay plates and placed in a 37°C 5% CO2 incubator overnight.

[0659] b) On day 2, the compound was diluted to 10 concentrations and added to the cells (final DMSO concentration was 0.05%) and placed in a 37°C 5% CO2 incubator for 7 days;

[0660] c) On day 8, 40 μl of 3D CTG reagent was added to each well, centrifuged at 320 rpm for 20 minutes, and allowed to stand at room temperature for 2 hours;

[0661] d) Using Envision readouts, calculate IC50 values;

[0662] 3.2 Experimental data processing method:

[0663] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (50% inhibitory concentration): Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope))

[0664] X: Log value of cpd concentration

[0665] Y: inhibition rate (%)

[0666] The experimental results are shown in Table 3 below:

[0667] Table 3

Claims

1. A compound as shown in formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, a tautomer thereof, a prodrug thereof, a metabolite thereof or an isotopic compound thereof: in, R 1 C6-C 14 The aromatic group, one or more R 1-1 Substituted C6~C 14 aryl, 6-14 membered heteroaryl or one or more R 1-2 substituted 6-14 membered heteroaryl, the 6-14 membered heteroaryl and the substituted one or more R 1-2 The heteroatoms in the substituted 6-14 membered heteroaryl are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3; R 1-1 and R 1-2 Each is independently hydroxyl, C1-C6 alkyl, C3-C8 cycloalkyl, halogen, NH2, CN, -O(C=O)NR 1-a R 1- b ,-OP(=O)(OR 1-c )2, -O(S=O)2-R 1-d , C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 alkyl substituted by one or more halogens, C1-C6 alkoxy substituted by one or more halogens, or C1-C6 alkoxy substituted by one or more R 1-e Substituted C3-C8 cycloalkyl, R 1-a , R 1-b and R 1-c Each is independently H or a C1-C6 alkyl group; R 1-d Independently for one or more R 1-d-1 Substituted C6~C 14 The aryl group; R 1-d-1 independently NO2; R 1-e , R 1-f are independently C1-C6 alkyl; R 2 is H, halogen or C1-C3 alkyl; R 3 is hydrogen, R 4 is a 7-12 membered bridged heterocycloalkyl or " 4-1 substituted 7-12 membered bridged heterocycloalkyl", wherein the heteroatoms in the 7-12 membered bridged heterocycloalkyl are independently one or more of N, O and S, and the number of heteroatoms is 1-3; or R 3 , R 4 Connected to form a 12-16-membered heterocycloalkyl group; the heteroatoms in the 12-16-membered heterocycloalkyl group are independently one or more of N, O and S, and the number of heteroatoms is 1-3; R 4-1 is a C1-C6 alkyl group; R 5 is a 4-12 membered heterocycloalkyl group or is replaced by one or more R 5-1 substituted 4-12 membered heterocycloalkyl, wherein the 4-12 membered heterocycloalkyl and the 5-1 The heteroatoms in the substituted 4-12 membered heterocycloalkyl are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3; R 5-1 are independently hydroxyl, C1-C6 alkyl, C6-C 14 Aryl, -O-C6-C 14 Aryl, one or more R 5-1-1 Substituted C1-C6 alkyl, one or more R 5-1-2 Substituted C6-C 14 Aryl or one or more R 5-1-3 Substituted-O-C6-C 14 Aryl; R 5-1-1 is hydroxy, halogen, 4-10 membered heterocycloalkyl or is replaced by one or more R 5-1-1-1a substituted 4-10 membered heterocycloalkyl; said 4-10 membered heterocycloalkyl and said 5-1-1-1a The heteroatoms in the substituted 4-10 membered heterocycloalkyl are independently 1, 2 or 3 of N, O or S, and the number of heteroatoms is 1, 2 or 3; R 5-1-1-1a Independently C6-C 14 Aryl or one or more R a Substituted C6-C 14 Aryl; R a are independently -C(=O)NH2; R 5-1-2 are independently -C(=O)NH2; R 5-1-3 are independently C1-C6 alkyl; n is 1, 2 or 3; A is CR 6 or N; R 6 is H, C1-C6 alkyl, cyano, halogen, or C1-C6 alkyl substituted by one or more halogens; The compound shown in formula I is not the following compound:

2. The compound of formula I as claimed in claim 1, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The compound represented by formula I is represented by formula I-1, I-2, I-3 or I-4: wherein X is N, O or S; n1 is independently 1, 2, 3 or 4; R 6 , R 7 Each is independently H, C1-C6 alkyl or halogen.

3. The compound as shown in formula I according to claim 1 or 2, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The compounds shown in Formula I, I-1, I-2, I-3 and I-4 satisfy one or more of the following conditions: (1)R 1 In the above, C6~C 14 The aromatic group or one or more R 1-1 Substituted C6~C 14 The C6~C 14 The aryl groups are independently C6~C 10 The aryl group is phenyl or naphthyl, preferably naphthyl, for example (2)R 1 wherein the 6-14 membered heteroaryl group may be replaced by one or more R 1-2 The C6-C 14 The heteroaryl groups may independently be C6-C 10 Heteroaryl, for example pyridyl, pyrimidinyl, indolyl, benzoxazolyl, benzimidazolyl, benzopyrazolyl, quinolyl, isoquinolyl, benzothiazolyl, pyridopyrazolyl, benzothiophenyl, for example (3)R 1-1 wherein the C1-C6 alkyl group substituted by one or more halogens is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, such as ethyl; (4)R 1-1 , R 1-2 wherein the C3-C8 cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, for example, cyclopropyl; (5)R 1-1 , R 1-2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example fluorine; (6)R 1-1 , R 1-2 In, the C2-C6 alkynyl group is a C2-C4 alkynyl group, such as ethynyl; (7)R 2 wherein the halogen is fluorine, chlorine, bromine or iodine, for example fluorine; (8)R 2 In the above, the C1-C3 alkyl group is methyl, ethyl, n-propyl, isopropyl; (9)R 4 wherein the 7-12 membered bridged heterocycloalkyl and the " 4-1 Substituted 7-12 membered bridged hetero The 7-12-membered bridged heterocycloalkyl in the "cycloalkyl" is independently an 8-membered bridged heterocycloalkyl or a 9-membered bridged heterocycloalkyl, the heteroatom is N, the number is 2, and it can be a bicyclo[3.2.1]octyl, for example It can also be a bicyclo[4.2.1]nonyl group, for example (10)R 3 , R 4 In the case where the 12-16-membered heterocycloalkyl is connected to form a 12-16-membered heterocycloalkyl, the 12-16-membered heterocycloalkyl is a 13-membered or 14-membered tricyclic heterocycloalkyl, the heteroatom is N or O, the number of N is 2, and the number of O is 1, for example (11)R 5 wherein the 4-12 membered heterocycloalkyl group and one or more R 5-1 The 4-12-membered heterocycloalkyl in the substituted 4-12-membered heterocycloalkyl is independently a 4-10-membered heterocycloalkyl; preferably a 5-6-membered monocyclic heterocycloalkyl, wherein the heteroatoms are N and / or O, and the number is 1 or 2; it may also be piperidinyl, piperazine or morpholinyl, and may further be (12)R 5 wherein the 4-12 membered heterocycloalkyl group and one or more R 5-1 The 4-12-membered heterocycloalkyl in the substituted 4-12-membered heterocycloalkyl is independently a 4-10-membered heterocycloalkyl, wherein the 4-12-membered heterocycloalkyl and one or more R 5-1 The 4-12-membered heterocycloalkyl in the substituted 4-12-membered heterocycloalkyl is independently an 8-membered bridged heterocycloalkyl, a 9-membered bridged heterocycloalkyl, a 9-membered spiro heterocycloalkyl or an 11-membered spiro heterocycloalkyl, and the heteroatom is N and / or O, and the number is 1 or 2, for example Another example is (13)R 5-1 wherein the C1-C6 alkyl group may be replaced by one or more R 5-1-1 The C1-C6 alkyl group in the substituted C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, methyl; (14)R 5-1 In the C6-C 14 Aryl, -O-C6-C 14 C6-C in aromatic groups 14 Aryl, one or more R 5-1-2 Substituted C6-C 14 C6-C in aromatic groups 14 The aromatic group and one or more R 5-1-3 Substituted-O-C6-C 14 C6-C in aromatic groups 14 The aryl groups are independently C6-C 10 The aryl group is phenyl or naphthyl, preferably phenyl; (15)R 5-1-1 wherein the 4-10 membered heterocycloalkyl group and one or more R 5-1-1-1a The 4-10 membered heterocycloalkyl in the substituted 4-10 membered heterocycloalkyl is independently a 5-6 monocyclic heterocycloalkyl, wherein the heteroatom is N and / or O, and the number is 1 or 2; it may also be piperidinyl, piperidinyl, Oxazine or morpholinyl, and can further be (16)R 5-1-1-1a In the C6-C 14 The aromatic group and one or more R a Substituted C6-C 14 C6-C in aromatic groups 14 The aryl groups are independently C6-C 10 The aryl group is phenyl or naphthyl, preferably phenyl; (17)R 5-1-3 wherein the C1-C6 alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl, for example, isopropyl; (14)n is 1.

4. The compound of formula I as claimed in claim 3, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The compound as shown in Formula I, I-1, I-2, I-3 or I-4 satisfies one or more of the following conditions: (1)R 1-1 In which the C1-C6 alkyl group is an ethyl group; (2)R 1-1 In the above, the C3-C8 cycloalkyl group is a cyclopropyl group; (3)R 1-1 wherein the halogen is fluorine or chlorine; (4)R 1-1 In, the C2-C6 alkynyl group is ethynyl; (5)R 1-2 In which the C1-C6 alkyl group is a methyl group; (6)R 1-2 In the formula (a), the C1-C6 alkyl group substituted by one or more halogens is trifluoromethyl; (7)R 2 wherein the halogen is fluorine; (8)R 4 wherein the 7-12 membered bridged heterocycloalkyl and the " 4-1 The 7-12-membered bridged heterocycloalkyl in the "substituted 7-12-membered bridged heterocycloalkyl" is (9)R 3 , R 4 In the case of a 12-16 membered heterocycloalkyl group, the 12-16 membered heterocycloalkyl group is (10)R 5 In the embodiment, the 4-12 membered heterocycloalkyl group is By one or more R 5-1 Replaced 4- The 12-membered heterocycloalkyl group is (11)R 5 wherein the 4-12 membered heterocycloalkyl group is or is replaced by one or more R 5-1 The 4-12-membered heterocycloalkyl in the substituted 4-12-membered heterocycloalkyl is independently an 8-membered bridged heterocycloalkyl, a 9-membered bridged heterocycloalkyl, a 9-membered spiro heterocycloalkyl or an 11-membered spiro heterocycloalkyl, and the heteroatom is N and / or O, and the number is 1 or 2, for example (12)n is 1.

5. The compound as shown in formula I according to claim 1 or claim 2, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The compound as shown in Formula I, I-1, I-2, I-3 or I-4 satisfies one or more of the following conditions: (1) R 1 for (2) R2 is fluorine; (3) R3 is hydrogen; (4)R 4 for (5)R 5 for (6)n is 1.

6. The compound of formula I as claimed in claim 1 or claim 2, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The compounds shown in formula I, I-1 and I-3 satisfy the following conditions: (1) R 1 for (2) R2 is fluorine; (3) R3 is hydrogen; (4)R 4 for (5)R 5 for (6)n is 1.

7. The compound as shown in formula I according to claim 1 or claim 2, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotopic compound, characterized in that: The compound as shown in Formula I, I-2, or I-4 satisfies the following conditions: (1) R 1 for (2) R2 is fluorine; (3)R 3 , R 4 In the case of a 12-16 membered heterocycloalkyl group, the 12-16 membered heterocycloalkyl group is (5)R 5 for (6) R6 is hydrogen; (7) R7 is hydrogen; (8) n1 is 1 or 2; (9)n is 1.

8. The compound of formula I as claimed in claim 1 or claim 2, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotopic compound, characterized in that: The compound as shown in Formula I, I-1, I-2, I-3 or I-4 is any of the following compounds: Preferably, the "*" in the compound indicates that it is a chemical bond of a stereo configuration. Any one of .

9. The compound of formula I as described in any one of claims 1 to 8, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The pharmaceutically acceptable salt of the compound shown in Formula I is the formate salt of the compound shown in Formula I or the hydrochloride salt of the compound shown in Formula I.

10. The compound of formula I as claimed in claim 1, its pharmaceutically acceptable salt, its solvate, its stereoisomer, its tautomer, its prodrug, its metabolite or its isotope compound, characterized in that: The pharmaceutically acceptable salt of the compound shown in Formula I is any of the following compounds:

11. A compound 16 or 16-a or a pharmaceutically acceptable salt thereof, having the structural formula shown below:

12. A pharmaceutical composition comprising a compound as shown in formula I as described in any one of claims 1 to 10, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, a tautomer thereof, a prodrug thereof, a metabolite thereof or an isotopic compound thereof, or a compound 16 or 16-a as described in claim 11 or a pharmaceutically acceptable salt thereof, preferably, the pharmaceutical composition also comprises a pharmaceutical excipient.

13. Use of substance A in the preparation of KRAS mutant protein inhibitors or drugs; The substance A is a compound as shown in formula I as described in any one of claims 1 to 10, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, a tautomer thereof, a prodrug thereof, a metabolite thereof, an isotopic compound thereof, a compound 16 or 16-a as described in claim 11 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 12; The drug is "for preventing or treating cancer" or "for preventing or treating cancer mediated by KRAS mutation".

14. The use according to claim 13, characterized in that The KRAS mutant protein is KRAS G12D mutant protein; and / or, the cancer is blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer or lung cancer; And / or, the cancer mediated by KRAS protein mutation is blood cancer, pancreatic cancer, MYH-related polyposis, colorectal cancer or lung cancer.

Citation Information

Patent Citations

  • KRAS G12D inhibitor and application thereof

    CN115557974A

  • KRAS g12d inhibitors

    WO2022192794A1

  • Pyrimidine heterocyclic compound and application thereof

    WO2022199587A1

  • Heterocyclic derivative, and preparation method therefor and use thereof in medicine

    WO2022206723A1

  • KRAS g12d inhibitors and uses thereof

    WO2023001141A1

Cited By

  • Cereblon-based KRAS degrading PROTACs and uses related thereto

    US12448399B2

  • KRAS G12D modulating compounds

    US12448400B2

  • Ras inhibitors

    WO2025240847A1

  • Methods of treating a ras protein-related disease or disorder

    WO2025255438A1

  • Therapeutic compositions and methods for managing treatment-related effects

    WO2025265060A1